

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
19 September 2002 (19.09.2002)

PCT

(10) International Publication Number
WO 02/072844 A1

(51) International Patent Classification⁷: C12N 15/67 (81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW.

(21) International Application Number: PCT/AU02/00351

(22) International Filing Date: 8 March 2002 (08.03.2002)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/274,770 9 March 2001 (09.03.2001) US

(71) Applicant (for all designated States except US): GENE STREAM PTY LTD [AU/AU]; 96 Chipping Road, City Beach, Western Australia 6015 (AU).

(72) Inventor; and

(75) Inventor/Applicant (for US only): DALY, John [AU/AU]; 96 Chipping Road, City Beach, Western Australia 6015 (AU).

(74) Agents: ARGAET, Victor, Peter et al.; Davies Collison Cave, Level 3, 303 Coronation Drive, Milton, Queensland 4064 (AU).

(84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— with international search report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.



WO 02/072844 A1

(54) Title: NOVEL EXPRESSION VECTORS

(57) Abstract: The present invention relates generally to expression vectors and their use in gene expression or gene regulation assays. More particularly, the present invention provides expression vectors and/or reporter vectors providing kinetics of protein expression with improved temporal correlation to promoter activity. Even more particularly, the invention provides expression vectors comprising a transcribable polynucleotide which comprises a sequence of nucleotides encoding an RNA element which modulates the stability of a transcript corresponding to said transcribable polynucleotide. The present invention provides, *inter alia*, novel vectors, useful for identifying and analysing *cis*- and *trans*-acting regulatory sequences/factors as well as vectors and genetically modified cell lines or organisms that are particularly useful for drug screening and drug discovery.

- 1 -

NOVEL EXPRESSION VECTORS

FIELD OF THE INVENTION

5 The present invention relates generally to vectors and their use in gene expression or gene regulation assays. More particularly, the present invention provides expression vectors and/or reporter vectors providing kinetics of protein expression with improved temporal correlation to promoter activity. The present invention provides, *inter alia*, novel vectors and cell lines useful for modulating gene expression, identifying and analysing regulatory sequences, new targets and reagents for therapeutic intervention in human diseases and for drug-screening.

10

BACKGROUND OF THE INVENTION

Bibliographic details of the publications referred to by author in this specification are

15 collected at the end of the description.

Reference herein to prior art, including any one or more prior art documents, is not to be taken as an acknowledgment, or suggestion, that said prior art is part of the state of the art.

20 The rapidly increasing sophistication of recombinant DNA technology is greatly facilitating research and development in the medical and allied health fields. A particularly important area of research is the use of expression vectors to study gene expression. However, until now, a real-time analysis of gene expression has been limited by the lack of suitably designed vectors.

25 Reporter assays permit an understanding of what controls the expression of a gene of interest e.g., DNA sequences, transcription factors, RNA sequences, RNA-binding proteins, signal transduction pathways and specific stimuli.

30 Furthermore, reporter assays can be used to identify aspects of gene regulation that serve as new targets for therapeutic intervention in human disease. Reporter assays can potentially be used to screen drugs for their ability to modify gene expression. However, the cost and time

- 2 -

required for current reporter assay systems, together with the lengthy response times, has limited this application.

Genomic sequences have promoter sequences, generally upstream of the coding region, which 5 dictate the cell specificity and inducibility of transcription and thereby affect the level of expression of protein products.

Specific sequence elements, typically rich in the nucleotide bases A and U and often located in the 3'-UTR of a gene, affect the stability of the mRNA and thereby affect the level of 10 expression of the protein product. RNA-binding proteins bind certain mRNA sequences and thereby regulate mRNA stability and protein expression. Other sequences modulate translational efficiency.

A common application of gene reporter assays is the study of DNA sequences that regulate 15 transcription. Typically, these sequences are located in the promoter region, 5' of the transcription start site. Such DNA elements are tested by cloning them into a similar site within a reporter plasmid, such that they drive and/or regulate transcription and therefore, expression of reporter protein. The reporter protein should be distinguishable from endogenous proteins and easily quantified. Various reporter proteins are used, the most common being luciferase, 20 chloramphenicol transferase (CAT) and β galactosidase (β -gal).

The reporter protein is quantified in an appropriate assay and often expressed relative to the level of a control reporter driven by a ubiquitous promoter such as for example the promoter 25 SV40. The control reporter must be distinguishable from the test reporter and is contained on a separate vector that is co-transfected with the test vector and used to control for transfection efficiency. Such assays are based on the premise that cells take up proportionally equal amounts of both vectors. Transient transfections of plasmid vectors are most commonly used.

The assays described above are used to identify a promoter region or the specific elements 30 within a promoter. Alternatively, they are used to study the response to various stimuli of a

- 3 -

promoter or regulatory element. In some applications, the reporter constructs, or the transfected cells, are placed into an organism to study promoter function *in vivo*.

Another application of these reporter assays is the study or measurement of signal transduction pathways upstream of a specific promoter. For example, a promoter dependent on mitogen activated protein kinase (MAPK) for transcription can be linked to a reporter construct and used to measure the level of MAPK activation (or MAPK-dependent transcription) in cells. This technique can be utilized with a variety of informative promoters or enhancers and can be applied to cells or living organisms such as transgenic mice. For example, a photon camera can be used to measure luciferase reporter activity in whole mice containing a luciferase reporter linked to a promoter of interest (Contag, *et al*, 1997).

10 Luciferase is by far the most commonly used reporter assay for *in vitro* systems. The Dual Luciferase assay (DLA; Promega, Madison, WI, USA), is an improvement over other 15 luciferase based systems in that both test and control reporter can essentially be measured in the same assay. As an example of current use, a typical DLA protocol is provided as follows:

20 The putative promoter element is cloned upstream of a firefly luciferase reporter gene such that it drives its expression. This plasmid is transiently transfected into a cell line, along with a control plasmid containing the *Renilla* luciferase gene driven by the SV40 promoter. ~2-50% of cells take up plasmid and express the reporters for ~3 days. The kinetics of expression involve an increase during the first ~24 h as luciferase protein accumulates, followed by a decrease from ~48 h as the number of plasmids maintained within the cells declines. 24-48 h after transfection, cells are harvested and lysed. Cell lysates are incubated with substrates 25 specific to firefly luciferase and activity (light emission) is measured using a luminometer (96 well plate or individual samples). Additional substrates are then added, which inactivate firefly luciferase but allow *Renilla* luciferase to generate light. *Renilla* luciferase activity can then be measured.

30 The level of firefly luciferase activity is dependent, not only on promoter activity, but also on transfection efficiency. This varies greatly, depending on the amount of DNA, the quality of

- 4 -

the DNA preparation and the condition of the cells. The co-transfected control plasmid (*Renilla* luciferase driven by the SV40 promoter) is used to correct for these variables, based on the premise that *Renilla* luciferase activity is proportional to the amount of firefly luciferase plasmid taken up by the cells. Data are expressed as firefly luciferase activity / *Renilla* luciferase activity.

5

The disadvantages of the Dual Luciferase assay are as follows:

- (i) Reagents are expensive and perishable and must be freshly prepared.
- 10 (ii) Generally this assay involves the preparation of cell lysates, which is time consuming and adds inaccuracy. e.g., loss of cells during lysis, pipetting errors, residual buffer/medium altering volumes.
- (iii) Each sample yields only one datum point being the total activity of the cell population.
- 15 No information is gained concerning the percentage of cells that express the reporter, nor the amount of expression per cell.
- (iv) The transfection control (*Renilla*) does not always correct for huge variation in transfection efficiencies because:
- 20 a. Certain DNA preparations transfet/express poorly (perhaps due to reduced proportion of supercoiled DNA), but do not cause a corresponding decrease in the amount of co-transfected control plasmid.
- 25 b. There is evidence of cross-talk between the promoters of the two plasmids, such that control reporter activity is dependent on the construct with which it is co-transfected, e.g., expression of *Renilla* luciferase seems highest when co-transfected with a plasmid containing a strong promoter. Interference between promoters has also limited, if not prevented, the use of single plasmids expressing both test and control reporters.
- 30

- 5 -

5 c. A common application of both transcriptional and post-transcriptional studies is to measure activation/suppression by various stimuli (e.g., PMA, EGF, hormones). Unfortunately, SV40, RSV, TK and probably many other ubiquitously expressed promoters are activated by a variety of stimuli. Since these promoters are used to drive expression of the transfection control reporter (*Renilla*), these reporters do not give a true reflection of transfection efficiency following such treatments. (Ibrahim *et al.* 2000).

10 d. Differences in the half-lives of firefly vs *Renilla* luciferase proteins and perhaps mRNAs make the whole system very time-sensitive.

15 e. Rapidly diminishing light emission, particularly for *Renilla* luciferase, require absolute precision in the timing of measurement.

f. The relatively long half-lives of luciferase proteins and mRNAs, effectively mask temporal changes in transcription (e.g., following various stimuli or treatments).

In existing post-transcriptional/mRNA stability reporter assays, candidate elements, thought to affect mRNA stability are cloned into the corresponding region of a reporter vector (e.g., firefly luciferase) driven by a constitutive promoter such as SV40 or RSV. Changes in expression relative to the empty vector (same vector without element of interest) are assumed to be the result of altered mRNA stability. As with the preliminary described transfection assays, a transfection control plasmid (e.g., *Renilla* luciferase driven by a constitutive promoter such as SV40 or RSV) is co-transfected to allow correction for transfection efficiency. These assays suffer from the following additional disadvantages:

(i). Existing vectors were not designed for post-transcriptional studies and have no means for switching off transcription.

- 6 -

5 (ii). The purpose of these protocols is to study the post-transcriptional effects of candidate mRNA elements. However, these elements can also affect transcription of the reporter at the level of DNA. Furthermore, since the endogenous promoter of the gene of interest is not used, any transcriptional effects seen, may have little physiological relevance.

10 Systems for studying mRNA stability exist but involve direct measurement of the mRNA rather than a protein reporter. Due to the labor-intensive nature of protocols for quantifying mRNA, such systems are far more time consuming.

15 One system, for example, utilizes the *c-fos* promoter, which responds to serum induction with a brief burst of transcription. Putative instability elements are cloned into the 3-UTR of a Beta Globin (BBB) construct, which expresses a very stable mRNA under the control of a serum-inducible (*c-fos*) promoter. Transfected cells (generally NIH 3T3 cells) are first serum starved and then exposed to medium containing serum. The brief nature of the transcriptional response allows the kinetics of reporter mRNA degradation to be followed in a time course. These assays suffer from the following disadvantages:

20 (i). This assay is very time consuming and is therefore not applicable to rapid screening.

25 (ii). Can only be used in cells that support serum inducibility of the *c-fos* promoter. For example, many tumor cell lines maintain *c-fos* promoter activity in the absence of serum.

(iii). In cells such as NIH 3T3 cells, which do have the desired serum response, serum deprivation causes a cell cycle block and subsequent addition of serum, releases the cells from this block in a synchronous manner. Therefore, mRNA stability can only be measured in specific stages of the cell cycle.

- 7 -

- (iv). In addition to activating the *c-fos* promoter, serum activates a multitude of other pathways, which introduce unwanted variables and prevent the study of more specific stimuli.
- 5 In another assay, cells are treated with drugs, such as Actinomycin D that inhibit transcription from all genes. The mRNA levels are measured in a time course to determine mRNA degradation rates. This system is used to study endogenous genes and suffer from the following disadvantages:
- 10 (i). Transcriptional inhibitors are extremely toxic at doses required such that mRNA stability is often being measured in stressed or dying cells.
- (ii). Transcription inhibitors possess numerous unwanted activities including stabilization of certain mRNAs.
- 15 (iii). The process blocks transcription from all genes such that many signal transduction cascades are blocked, whereas others are activated. Therefore, results may not be physiologically relevant.
- 20 (iv). The technique is extremely labor intensive.
- (v). The technique is highly variable within and between assays.
- 25 (vi). The technique is often not sensitive enough for transient transfection reporter assays, particularly in cells with a low transfection efficiency.

There is a need therefore to develop improved vectors and systems for conducting gene expression assays and in particular post-translational and post-transcriptional assays as well as assays that permit a more real-time determination of changes in gene expression.

SUMMARY OF THE INVENTION

Throughout this specification, unless the context requires otherwise the word "comprise", and variations such as "comprises" and "comprising", will be understood to imply the inclusion of

5 a stated integer or step or group of integers or steps but not the exclusion of any other integer or step or group of integers or steps. The present invention is not to be limited in scope by the specific embodiments described herein, which are intended for the purposes of exemplification only. Functionally-equivalent products, compositions and methods are clearly within the scope of the invention, as described herein.

10

In accordance with the present invention, the inventor has developed a series of vectors and methods which permit *inter alia* modulation and determination of transcript stability and/or improved real-time determination of gene expression.

15

Nucleotide sequences are referred to by sequence identifier numbers (SEQ ID NO:). The SEQ ID NOs: correspond numerically to the sequence identifiers <400>1, <400>2, etc. A sequence listing is provided after the claims.

20

One aspect of the present invention is directed to an expression vector comprising a transcribable polynucleotide which comprises a sequence of nucleotides encoding an RNA element which modulates the stability of a transcript corresponding to said transcribable polynucleotide. As used herein the stability of a transcript may correspond to the half-life of the transcript.

25

Another aspect of the present invention contemplates an expression vector comprising a transcribable polynucleotide which comprises a sequence of nucleotides encoding an RNA element which modulates the stability of a transcript corresponding to said transcribable polynucleotide; wherein said RNA element is a destabilising element which reduces the stability of said transcript.

30

In a related embodiment the present invention contemplates an expression vector comprising

- 9 -

a transcribable polynucleotide which comprises a sequence of nucleotides encoding an RNA element which modulates the stability of a transcript corresponding to said transcribable polynucleotide; wherein said RNA element is a stabilising element which increases the stability of said transcript.

5

Another aspect of the present invention contemplates an expression vector comprising a transcribable polynucleotide which comprises a sequence of nucleotides encoding an RNA element wherein said RNA element is a destabilising element which reduces the stability of a transcript corresponding to said transcribable polynucleotide and wherein said transcribable 10 polynucleotide comprises a polynucleotide of interest and encodes a polypeptide.

Yet another aspect of the present invention contemplates an expression vector comprising a transcribable polynucleotide which comprises a sequence of nucleotides encoding an RNA element wherein said RNA element is a destabilising element which reduces the stability of 15 a transcript corresponding to said transcribable polynucleotide and wherein said transcribable polynucleotide comprises a polynucleotide of interest and encodes a reporter polypeptide.

Even yet another aspect of the present invention contemplates an expression vector comprising 20 a transcribable polynucleotide which comprises a sequence of nucleotides encoding an RNA element wherein said RNA element is a destabilising element which reduces the stability of said transcript and wherein said transcribable polynucleotide comprises a sequence of nucleotides encoding a reporter polypeptide.

Still another aspect of the present invention is directed to an expression vector comprising a 25 transcribable polynucleotide which comprises a sequence of nucleotides encoding an RNA element which modulates the stability of a transcript corresponding to said transcribable polynucleotide; wherein said RNA element is a destabilising element which reduces the stability of a transcript corresponding to said transcribable polynucleotide and wherein said vector comprises one or more members selected from the group consisting of:

30

(i) a multiple cloning site for introducing a sequence of nucleotides;

- 10 -

- (ii) a reporter gene;
- 5 (iii) a promoter and/or enhancer for regulating expression of said transcribable polynucleotide;
- (iv) a polyadenylation sequence;
- 10 (v) a selectable marker gene; and
- (vi) an origin of replication.

Even still another aspect of the present invention contemplates a cell containing a vector according to the present invention comprising a transcribable polynucleotide which comprises a sequence of nucleotides encoding an RNA element which modulates the stability of a transcript corresponding to said transcribable polynucleotide.

Still another aspect of the present invention contemplates a cell containing a vector according to the present invention comprising a transcribable polynucleotide which comprises a sequence of nucleotides encoding an RNA element which modulates the stability of a transcript corresponding to said transcribable polynucleotide; wherein said RNA element is a destabilising element which reduces the stability of said transcript.

A related aspect of the instant invention considers a genetically modified non-human organism comprising a transcribable polynucleotide which comprises a sequence of nucleotides encoding an RNA element which modulates the stability of a transcript corresponding to said transcribable polynucleotide; wherein said RNA element is a destabilising element which reduces the stability of said transcript.

30 Yet a further embodiment of the present invention contemplates a method for determining expression of a polynucleotide of interest, said method comprising expressing said

- 11 -

polynucleotide of interest from an expression vector for a time and under conditions sufficient for RNA and protein synthesis to occur, said vector comprising a transcribable polynucleotide which comprises said polynucleotide of interest and a sequence of nucleotides encoding an RNA element which modulates the stability of a transcript corresponding to said transcribable 5 polynucleotide; and wherein said expression vector comprises one or more members selected from the group consisting of:

10 (i) a multiple cloning site for introducing a sequence of nucleotides;

(ii) a reporter gene;

(iii) a promoter and/or enhancer for regulating expression of said transcribable polynucleotide;

15 (iv) a polyadenylation sequence;

(v) a selectable marker gene; and

(vi) an origin of replication;

20 and measuring the level and/or functional activity of an expression product of the transcribable polynucleotide over time compared to a control wherein said element enhances the temporal correlation between the activity of the promoter and/or enhancer that is operably connected to said transcribable polynucleotide and the level and/or functional activity of said expression 25 product.

In still yet a further embodiment, the present invention contemplates a method for identifying a nucleotide sequence encoding an RNA element which modulates the stability of an RNA transcript, said method comprising introducing a test nucleotide sequence into an expression 30 vector whereby said nucleotide sequence is connected to a polynucleotide encoding a reporter protein to form a transcribable polynucleotide which is operably connected to a promoter

- 12 -

and/or enhancer; expressing said transcribable polynucleotide for a time and under conditions sufficient for RNA and protein synthesis to occur; and wherein said expression vector comprises one or more members selected from the group consisting of:

- 5 (i) a multiple cloning site for introducing said test nucleotides sequence;
- (ii) a polyadenylation sequence;
- (iii) a selectable marker gene; and
- 10 (iv) an origin of replication;

and measuring the level and/or functional activity of an expression product of said transcribable polynucleotide over time compared to that of a control vector in the absence of
15 said nucleotide sequence, wherein a level and/or functional activity which is different to that of the control vector over that time is indicative of a nucleotide sequence that encodes said RNA element.

- 13 -

BRIEF DESCRIPTION OF THE DRAWINGS

Figure 1 is a schematic representation of expression vectors encoding a destabilising mRNA.

5 **Figure 2** is a schematic representation of transcription reporter vectors; Figure 2a shows vector series 2; Figure 2b shows vector series 3 and Figure 2c shows vector series 4.

Figure 3 is a schematic representation of Bi-directional transcription reporter vectors; Figure 3a shows vector series 5 and Figure 3b shows vector series 6.

10 **Figure 4** is a schematic representation of reporter vectors for studying post-transcriptional regulation; Figure 4a shows vector series 7 and Figure 4b shows vector series 8.

15 **Figure 5** is a graphical representation showing reporter activity as a measure against the amount of DNA transfected. A single DNA preparation of a plasmid encoding firefly luciferase was mixed at a 30:1 ratio with a separate plasmid encoding *Renilla* luciferase. Both DNA preparations appeared normal in spectrophotometry (OD260/280) and on ethidium bromide stained agarose gels (data not shown). Different volumes of this mixture were transfected into cells such that the total quantity of DNA was 1, 2 or 3 micrograms but the ratio of firefly to 20 *Renilla* plasmids remained the same.

25 Fig. 5A is a graphical representation showing that *Renilla* luciferase activity was dependent on the amount of DNA transfected. However, firefly luciferase activity (Fig. 5B) did not increase with increasing amounts of DNA, perhaps because the firefly DNA preparation was of poor quality. Consequently, the firefly/*Renilla* ratio (Fig. 5C), which would typically be used as a measure of the firefly promoter activity, varied considerably depending on the amount of DNA used. These data demonstrate that co-transfections with *Renilla* plasmids do not adequately control for the transfection efficiency of the firefly plasmid

30 **Figure 6** is a graphical representation showing reporter activity for various promoter systems using the Dual Luciferase Assay. Six different promoter fragments (numbered 1-6) were cloned

- 14 -

into pGL3 firefly luciferase plasmids. One microgram of each clone was co-transfected with 30ng of *Renilla* (transfection control) plasmid, driven by an SV40 promoter. Firefly and *Renilla* luciferase activities were measured using the Dual Luciferase Assay (Promega, Madison, WI, USA). Results are expressed as *Renilla* luciferase activity (A), Firefly luciferase 5 activity (B) and firefly divided by *Renilla* activity (C). Similar results were seen in multiple experiments using at least 2 different preparations of each construct.

Renilla luciferase activity (Fig. 6A) is intended as a transfection control and analysis of this result alone would suggest an unusually high variation in transfection efficiency. For example, 10 10 *Renilla* luciferase activity is 3.5 fold higher when co-transfected with construct 4 compared to co-transfection with construct 3. Variations in DNA quality or errors in the quantification of DNA seem unlikely as sources of error since the same pattern was seen with a separate set of DNA preparations (data not shown).

15 Firefly luciferase activity (Fig. 6B) is influenced by both transfection efficiency and differences between promoters 1-6. The pattern of differences is similar to that seen with *Renilla* (Fig. 6A). For example, 3 and 6 are low whilst 4 and 5 are high. However these differences between constructs are more marked with firefly (e.g., construct 4 is 12 fold higher than construct 3), suggesting that the activity of promoters 1-6 is somehow affecting expression of *Renilla* (or 20 vice versa).

Firefly/*Renilla* (Fig. 6C) is considered to be a measure of true firefly promoter activity (1-6) after correction for transfection efficiency (*Renilla*). Again a similar pattern is seen, suggesting that indeed 3 and 6 are the weakest promoters whilst 4 and 5 are the strongest. Whilst it is 25 possible that promoter activity (Fig. 6C) coincidentally correlated with transfection efficiency (Fig. 6A), this possibility seems extremely unlikely given that similar results were obtained with numerous different constructs and multiple different preparations of the same construct. It seems more likely that the level of expression of *Renilla* luciferase is affected by the strength of the promoter construct with which it is co-transfected. Consequently, apparent differences 30 between promoters 1-6 are likely to be an underestimation of the true differences.

- 15 -

Figure 7 is a graphical representation showing different reporter levels for BTL, BTG2, BTG1 and BTG1N4 expression vectors on a time course after blocking transcription. Tet-Off HeLa cells were transfected with the following reporter plasmids, each containing a TRE promoter linked to a reporter gene; BTL (luciferase), BTG2 (d2EGFP), BTG1 (d1EGFP) and

5 BTG1N4 (same as BTG1 but with 4 copies of the nonamer UUAUUUAUU present in the 3'UTR-encoding region). Ten hrs after transfection, each flask of cells was split into multiple small plates. Doxycycline (10 µg/ml) was added at 24 hrs after transfection (time zero) to block transcription of the reporter genes. Reporter levels (fluorescence or luminescence) were measured at this and subsequent time points, as described in Example 14, and presented as the

10 percentage of time zero. No decrease in luciferase activity (BTL) was seen during the 10 hr time-course. The 2 hr half-life EGFP construct (BTG2) showed a moderate response to the doxycycline-induced block in transcription and a faster response was seen with the 1 hr half-life EGFP (BTG1). The construct containing the nonamers (BTG1N4), however, showed by far the fastest response to this block in transcription.

15

Figure 8 is a graphical representation showing the data used for Fig. 7 displayed on a linear scale. The doxycycline-induced block in transcription is detectable as a 50% block in reporter levels after approximately 6.5 hrs with BTG1. However, this is reduced to less than 3 hrs by inclusion of the nonamers (BTG1N4).

20

Figure 9 is a graphical representation showing the effect of different numbers (1, 2 or 4) of nonamer RNA destabilising elements. A time-course was performed as described in Fig. 7, except with time zero defined as 4 hrs after addition of doxycycline to eliminate the effect of the delay in the action of this drug. The presence of a single nonamer (BTG1N1) was sufficient

25 to increase the “effective rate of decay,” whereas progressively stronger effects were seen with 2 nonamers (BTG1N2) and 4 nonamers (BTG1N4). The latter construct showed an “effective half-life” of ~1 hr 20 mins, which is little more than the 1 hr half-life of the protein alone.

Figure 10 is a graphical representation showing changing reporter levels over time in the

30 absence of a transcriptional block. A time-course was performed as described in Fig. 7. However, the data presented represent samples not treated with doxycycline and measured at

- 16 -

24 hrs after transfection (start) or 34 hrs after transfection (finish). Consistent expression levels were seen only with BTG1N4.

5 **Figure 11** is a graphical representation showing changes in reporter levels over time in the absence of a transcriptional block. A time-course was performed as described in Fig. 7. BTG1fos contains the c-fos ARE. These data demonstrate that different types of mRNA destabilising elements can be used to achieve the same effect.

10 **Figure 12** is a graphical representation showing that RNA destabilising elements are useful in determining expression when a Luciferase reporter protein is used. A further enhancement would be expected using a luciferase reporter protein with protein destabilising elements. A time-course was performed as described in Fig. 7, using two luciferase-expressing constructs. BTL contains the standard Firefly luciferase-coding region and 3'UTR (derived from pGL3-Basic; Promega), whereas BTLN6 contains 6 copies of the nonamer UUAUUUUAUU in the 15 3'UTR.

20 **Figure 13** is a graphical representation showing reporter levels over time using DsRed destabilised by RNA destabilising elements and protein destabilising elements. A time course was performed as described in Fig. 7 and Example 14. The constructs used were DsRed2 (BTR), DsRed-MODC (BTR1) and DsRed-MODC containing 4 UUAUUUUAUU nonamers in the 3'UTR (BTR1N4). After blocking transcription with doxycycline, red fluorescence continues to increase with all constructs. This is substantially reduced by the protein destabilising element and further reduced by the mRNA destabilising element.

25 **Figure 14** is a graphical representation showing a time-course was performed as described in Fig. 7. All of the mRNA destabilising elements tested were very effective at increasing the rate of decay compared to controls (BTG1). These data show that the c-myc ARE is an effective destabilising element (BTG1myc) and that a modest increase in destabilising activity can be obtained by combining the myc ARE with 4 nonamers (BTG1N4myc). Six nonamers 30 (BTG1N6) also appeared to destabilise somewhat more than 4 nonamers (BTG1N4).

DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS**Definitions**

5

By "3'UTR" is meant the region of a polynucleotide downstream of the termination codon of a protein-encoding region of that polynucleotide, which is not translated to produce protein.

By "5'UTR" is meant 5' (upstream) untranslated region of an mRNA. Also used to refer to the DNA region encoding the 5'UTR of the mRNA.

By "About" is meant a quantity, level, value, dimension, size, or amount that varies by as much as 30%, preferably by as much as 20%, and more preferably by as much as 10% to a reference quantity, level, value, dimension, size, or amount.

By "ARE" is meant an AU-rich element in mRNA i.e., a sequence that contains a high proportion of adenine and uracil nucleotides. Also used to refer to the DNA region encoding such an mRNA element.

By "*Biologically active fragment*" is meant a fragment of a full-length reference polynucleotide or polypeptide which fragment retains the activity of the reference polynucleotide or polypeptide, respectively.

By "*c-fos*" is meant an immediate early gene, briefly induced by mitogenic signals

By "*CAT:*" is meant Chloramphenicol acetyltransferase. A bacterial enzyme often used as a reporter.

By "*d1EGFP*" is meant a variant of EGFP that is fused to a mutated PEST sequence and consequently has a half-life of only about 1 hour. Similarly, d1ECFP and d1EYFP are also available. A destabilised variant of DsRed could be made in the same way. Henceforth referred to as d1DsRed.

- 18 -

By "*d2EGFP*" is meant a mutant form of EGFP variants that is fused to a PEST sequence and consequently has a half-life of only 2 hours. Similarly, d2ECFP (cyan) and d2EYFP (yellow) are also available. A destabilised variant of DsRed could possibly be made in the same way. Henceforth referred to as d2DsRed.

By "*dEGFP*" is meant a general term for all destabilised variants of EGFP (including all colors) formed. (Li *et al*).

By "*DNA*" is meant deoxyribonucleic acid.

By "*Derivative*" is meant a polynucleotide or polypeptide that has been derived from a reference polynucleotide or polypeptide, respectively, for example by conjugation or complexing with other chemical moieties or by post-transcriptional or post-translational modification techniques as would be understood in the art.

By "*DsRed*" is meant the red fluorescent protein isolated from the IndoPacific sea anemone relative *Discosoma* species.

By "*ECFP*" is meant the mutant form of EGFP with altered excitation/emission spectra that fluoresces cyan colored light.

By "*EGF*" is meant Epidermal growth factor

By "*EGFP*" is meant the enhanced green fluorescent protein. A mutant form of GFP with enhanced fluorescence. (Cormack *et al*).

By "*ELISA*" is meant the enzyme-linked immunosorbent assay

By "*ErbB2*" is meant the second member of the epidermal growth factor receptor family. Also known as HER-2

By "*Exon*" is meant the sequences of an RNA primary transcript that are part of a messenger RNA molecule, or the DNA that encodes such sequences. In the primary transcript neighbouring exons are separated by introns.

By "*Expression Vector*" is meant a vector that allows a cloned segment of DNA to be expressed inside a cell.

By "*EYFP*" is meant a mutant form of EGFP with altered excitation/emission spectra that fluoresces yellow colored light.

- 19 -

By "*Firefly Luciferase*" is meant

the enzyme derived from the luc gene, cloned from the firefly. Catalyzes a reaction using D-luciferin and ATP in the presence of oxygen and Mg⁺⁺ resulting in light emission. Often used as a reporter.

By "*Flow Cytometry*" is meant

a method, in which live or fixed cell suspensions are applied to a flow cytometer that individually measures an activity or property of a detectable label associated with the cells of the suspension. Labelling of cells can occur, for example, via fluorescent compounds or by antibodies covalently attached to a specific fluorescent compound. Several different excitation/emission wavelengths can be tested simultaneously to measure different types of fluorescence. Sub-populations of cells with desired characteristics (fluorescence, cell size) can be gated such that further statistical analyses apply only to the gated cells. Flow cytometers equipped with a cell sorting option can physically separate cells with the desired fluorescence and retrieve those (live) cells in a tube separate from the remainder of the initial cell population. Also referred to as FACS (fluorescence activated cell sorting).

By "*Gene*" is meant

the segment of DNA that encodes a RNA molecule. The term "gene" sometimes but not always includes the promoter region.

By "*GFP*" is meant

a fluorescent protein (Tsien *et al*), which is isolatable from the jellyfish *Aequoria victoria*, and which can be used as a reporter protein. DNA constructs encoding GFP can be expressed in mammalian cells and cause the cells to fluoresce green light when excited with specific wavelengths. The term "GFP" is used herein to refer to all homologues and analogues, including colour variants and fluorescent proteins derived from organisms other than *Aequoria victoria* (e.g., DSRed, Clonetech; hrGFP, Stratagene).

By "*Half-life*" is meant

the time taken for half of the activity, amount or number of molecules to be eliminated.

By "*Intron*" is meant

a non-coding sequence within a gene, or its primary transcript, that is removed from the primary transcript and is not present in a corresponding messenger RNA molecule.

- 20 -

By "*Luciferase*" is meant

the commonly used reporter enzyme that catalyses a reaction, which leads to light emission. Exogenous substrates are added and the reaction is quantified using a luminometer. The substrate requirements for firefly and *Renilla* luciferases are different, allowing the two to be distinguished in the Dual Luciferase Assay (Promega, Madison, WI, USA).

By "*MAPK*" is meant

Mitogen Activated Protein Kinase. Includes several different kinases involved in intracellular signal transduction pathways that lead to growth or apoptosis (cell death). The term "MAPK" is sometimes used in reference to two specific MAPKs, Erk1 and Erk2 (extracellular regulated kinases 1 and 2).

By "*MCMV*" is meant

Minimal CMV promoter. Does not activate transcription on its own but can be linked to a TRE to provide tetracycline (and doxycycline)-dependent transcription.

By "*MCS*" is meant

Multiple Cloning Site. The region of a DNA vector that contains unique restriction enzyme recognition sites into which a DNA fragment can be inserted. The term "MCS" as used herein, also includes any other site that assists the insertion of DNA fragments into the vector. For example, a T overhang (Promega, Madison, WI, USA), which allows direct insertion of fragments generated by polymerase chain reaction (PCR).

By "*mRNA*" is meant

Messenger RNA. A "transcript" produced in a cell using DNA as a template, which itself encodes a protein. mRNA is typically comprised of a 5'UTR, a protein encoding region and a 3'UTR. mRNA has a limited half-life in cells, which is determined, in part, by stability elements, particularly within the 3'UTR but also in the 5'UTR and protein encoding region.

By "*MODC*" is meant

Mouse ornithine decarboxylase or the portion and/or derivative thereof containing a PEST sequence.

By "*Modulating*" is meant

increasing or decreasing, either directly or indirectly, the stability of a molecule of interest.

- 21 -

By "*operably connected*" or "*operably linked*" and the like is meant

a linkage of polynucleotide elements in a functional relationship. A nucleic acid is "*operably linked*" when it is placed into a functional relationship with another nucleic acid sequence. For instance, a promoter or enhancer is operably linked to a coding sequence if it affects the transcription of the coding sequence. Operably linked means that the nucleic acid sequences being linked are typically contiguous and, where necessary to join two protein coding regions, contiguous and in reading frame. A coding sequence is "*operably linked to*" another coding sequence when RNA polymerase will transcribe the two coding sequences into a single mRNA, which is then translated into a single polypeptide having amino acids derived from both coding sequences. The coding sequences need not be contiguous to one another so long as the expressed sequences are ultimately processed to produce the desired protein. "*Operably connecting*" a promoter to a transcribable polynucleotide is meant placing the transcribable polynucleotide (e.g., protein encoding polynucleotide or other transcript) under the regulatory control of a promoter, which then controls the transcription and optionally translation of that polynucleotide. In the construction of heterologous promoter/structural gene combinations, it is generally preferred to position a promoter or variant thereof at a distance from the transcription start site of the transcribable polynucleotide, which is approximately the same as the distance between that promoter and the gene it controls in its natural setting; i.e.: the gene from which the promoter is derived. As is known in the art, some variation in this distance can be accommodated without loss of function. Similarly, the preferred positioning of a regulatory sequence element (e.g., an operator, enhancer etc) with respect to a transcribable polynucleotide to be placed under its control is defined by the positioning of the element in its natural setting; i.e. the genes from which it is derived.

- 22 -

The term "*pA*" is meant

used in diagrams here to indicate a poly adenylation site. A DNA sequence that serves as the site to stop transcription and add to the immature mRNA, a polyA tail. Various pA sequences from SV40 virus genes or the β galactosidase gene or other sources, including synthetic polyadenylation sites can be used in expression vectors for this purpose.

The term "*PEST*" refers

to an amino acid sequence that is enriched with the amino acids proline (P), glutamic acid (E), serine (S) and threonine (T). Proteins containing PEST sequences have shortened half-lives.

By "*Plasmid*" is meant

a Circular DNA vector. Plasmids contain an origin of replication that allows many copies of the plasmid to be produced in a bacterial (or sometimes eukaryotic) cell without integration of the plasmid into the host cell DNA.

By "*Polynucleotide*" or "*Nucleic acid*" is meant

linear sequences of nucleotides, including DNA or RNA, which may be double-stranded or single-stranded..

By "*Polypeptide*", "*Peptide*" or "*Protein*" is meant

a polymer of amino acids joined by peptide bonds in a specific sequence.

By "*Promoter*" is meant

a region of DNA, generally upstream (5') of the mRNA encoding region, which controls the initiation and level of transcription. This term also includes within its scope inducible, repressible and constitutive promoters.

By "*PMA*" is meant

Phorbol myristoloic acid

By "*Renilla Luciferase*" is meant

that derived from sea pansy (*Renilla reniformis*), utilizes oxygen and coelenterate luciferin (coelenterazine) to generate light emission

By "*Reporter Vector*" is meant

a expression vector containing a "Reporter Gene" that encodes a protein or polypeptide (or mRNA) that can be easily assayed. Typically, the reporter gene is linked to regulatory sequences, the function or activity of which, is being tested.

- 23 -

By " <i>Reporter</i> " is meant	a molecule, typically a protein or polypeptide, that is encoded by a reporter gene and measured in a reporter assay. Current systems generally utilize an enzymatic reporter and measure reporter activity.
By " <i>RNA</i> " is meant	Ribonucleic Acid.
By " <i>rtTA</i> " is meant	Reverse tTA (see below), which binds the TRE and activates transcription only in the presence of tetracycline or doxycycline.
By " <i>SEAP</i> " is meant	Secreted alkaline phosphatase reporter gene.
By " <i>SKBR3</i> " is meant	the human breast cancer cell line that overexpresses ErbB2.
By " <i>Stringent conditions</i> " is meant	temperature and ionic conditions under which only nucleotide sequences having a high frequency of complementary bases will hybridise. The stringency required is nucleotide sequence dependent and depends upon the various components present during hybridisation and subsequent washes, and the time allowed for these processes. Generally, in order to maximise the hybridisation rate, non-stringent hybridisation conditions are selected; about 20 to 25° C lower than the thermal melting point (T_m). The T_m is the temperature at which 50% of specific target sequence hybridises to a perfectly complementary probe in solution at a defined ionic strength and pH. Generally, in order to require at least about 85% nucleotide complementarity of hybridised sequences, highly stringent washing conditions are selected to be about 5 to 15° C lower than the T_m . In order to require at least about 70% nucleotide complementarity of hybridised sequences, moderately stringent washing conditions are selected to be about 15 to 30° C lower than the T_m . Highly permissive (low stringency) washing conditions may be as low as 50° C below the T_m , allowing a high level of mis-matching between hybridised sequences. Those skilled in the art will recognise that other physical and chemical parameters in the hybridisation and wash stages can also be altered to affect the outcome of a detectable hybridisation signal from a specific level of homology between target and probe sequences.

- 24 -

"SV40/CMV/RSV"

to refer to promoter elements derived from simian virus, cytomegalovirus and rous sarcoma virus respectively. Generally, these promoters are thought to be constitutively active in mammalian cells.

By "TetO" is meant

the Tet operator DNA sequence derived from the *E. coli* tetracycline-resistance operon.

By "Tet-Off Cell Lines" is meant

cell lines stably expressing tTA such that tetracycline or doxycycline will shut off transcription from TRE promoters.

By "Tet-On Cell Lines" is meant

cell lines stably expressing rtTA such that tetracycline or doxycycline will turn on transcription from TRE promoters.

By "Transcription" is meant

the process of synthesizing a RNA molecule complementary to the DNA template.

By "Transfection" is meant

the process during which a plasmid or DNA fragment is inserted into a eukaryotic cell. Typically, 2-50% of cells take up the plasmid and express the protein product for ~3 days without incorporating the plasmid DNA into the cell's chromosomes (= transient transfection). A small proportion of these cells will eventually incorporate the plasmid DNA into their genome and permanently express the protein product (= stable transfection).

By "Translation" is meant

the process whereby an mRNA molecule is used as a template for protein synthesis.

By "TRE" is meant

here to define any Tetracycline Responsive Element (Gossen *et al*), generally combined with a minimal promoter such that transcription occurs only via the binding of exogenous factors (e.g., tTA or rtTA) to the TRE. Preferred embodiments of this invention utilize a TRE comprised of 7 repeats of the tetO sequence linked to a minimal CMV promoter (mCMV) (Clontech Laboratories Inc., Palo Alto, CA, USA).

By "tTA" is meant

Tetracycline-controlled transactivator, which is comprised of the Tet repressor protein (TetR) and the VP16 activation domain, such that it binds the TRE and activates transcription, only in the absence of tetracycline or doxycycline.

- 25 -

By "TS" is meant

Thromboxane synthase promoter.

By "Variant" is meant

a polynucleotide or polypeptide displaying substantial sequence identity with a reference polynucleotide or polypeptide, respectively. Variant polynucleotides also include polynucleotides that hybridise with a reference sequence under stringent conditions. These terms also encompass polynucleotides which differ from a reference polynucleotide by the addition, deletion or substitution of at least one nucleotide. In this regard, it is well understood in the art that certain alterations inclusive of mutations, additions, deletions and substitutions can be made to a reference polynucleotide whereby the altered polynucleotide retains the biological function or activity of the reference polynucleotide. The terms "polynucleotide variant" and "variant" also include naturally occurring allelic variants. With regard to variant polypeptides, it is well understood in the art for example that some amino acids may be changed to others with broadly similar properties without changing the nature of the activity of the polypeptide (conservative substitutions).

By "Vector" is meant

a vehicle for inserting a foreign DNA sequence into a host cell and/or amplifying the DNA sequence in cells that support replication of the vector. Most commonly a plasmid but can also be a phagemid, bacteriophage, adenovirus or retrovirus.

By "vEGFP" "EGFP variants" or "variant of EGFP" is meant the different color variants of EGFP and/or the different half-life variants.

By "vGFP" is meant

all variants of GFP; including homologues and analogues such as DsRed, also EGFP variants or destabilised GFP variants.

The present invention provides *inter alia* expression vectors which modulate the stability of transcripts and consequently, the amount of protein produced by the vector. Although expression vectors which increase the stability of a transcript are clearly encompassed by the

5 present invention, a particularly preferred embodiment focuses on destabilising transcripts. Here transcript stability can be reduced by the addition of one or more destabilising elements to, or by the removal of one or more stability elements (e.g., a poly A tail) from, a transcribable polynucleotide. Compared to existing expression vectors, the vector of the present invention

- 26 -

provides kinetics of protein expression with improved temporal correlation to the promoter activity, e.g., by reducing the time lag between decreased promoter activity and decreased levels of a corresponding expression product.

- 5 Accordingly, one aspect of the present invention is directed to an expression vector comprising a transcribable polynucleotide which comprises a sequence of nucleotides encoding an RNA element which modulates the stability of a transcript corresponding to said transcribable polynucleotide.
- 10 The term "modulates" in the context of transcript stability refers to increasing or decreasing the stability of a transcript and optimal amounts of modulation depends upon the particular application. Without limiting the present invention to any one particular theory or mode of operation, where the RNA element is a sequence of nucleotides which destabilises the transcript, it is envisaged that the element directly or indirectly targets the transcript for
- 15 degradation.

As used herein the term "destabilising element" refers to a sequence of amino acids or nucleotides which reduces the half-life of a protein or transcript, respectively, inside a cell. Accordingly, an "RNA destabilising element" comprises a sequence of nucleotides which

- 20 reduces the intracellular half-life of an RNA transcript and a "protein destabilising element" comprises a sequence of amino acids which reduces the intracellular half-life of a protein.

The extent of the reduction sought depends upon the particular application. In a preferred embodiment the extent of RNA destabilisation significantly improves the temporal correlation

- 25 between promoter activity and reporter levels or activity in expression vectors compared to vectors without destabilisation elements. In relation to increasing transcript stability, optimum levels of stability will again depend upon the application.

An "RNA stabilising element" is a sequence of nucleotides which increases the intracellular

- 30 half-life.

- 27 -

"RNA" molecules include all RNA molecules such as mRNA, heterogenous nuclear RNA (hnRNA), small nuclear RNA (snRNA), small nucleolar RNA (snoRNA), small cytoplasmic RNA (scRNA), ribosomal RNA (rRNA), translational control RNA (tcRNA), transfer RNA (tRNA), eRNA, messenger-RNA-interfering complementary RNA (micRNA) or interference RNA (iRNA) and mitochondrial RNA (mtRNA).

Messenger RNA (mRNA) is a preferred form of RNA.

In the context of reducing the intracellular half-life of a molecule selected from an RNA transcript or an encoded protein of interest, (a) one or more destabilising elements and/or (b) one or more stabilising elements are typically chosen to confer a level of enhanced degradation on the molecule, which thereby reduce(s) the intracellular half-life of the molecule to a half-life that is suitably less than about 24 hours, more preferably less than about 10 hours, even more preferably less than about 5 hours, even more preferably less than about 3 hours, even more preferably less than about 1 hour, even more preferably less than about 30 minutes, even more preferably less than about 15 minutes, even more preferably less than about 10 minutes, even more preferably less than about 5 minutes, and still even more preferably less than about 3 minutes. The half-life of an RNA transcript or an encoded protein of interest preferably corresponds to the lowest half-life that provides a steady-state expression level of at least 10 fold the minimum detectable level of the transcript or encoded protein.

The intracellular or intracellular-like conditions are preferably physiological for the cell type. The temperature of the intracellular or intracellular-like conditions is preferably physiological for the cell type. Exemplary temperatures for mammalian cells range suitably from about 30° C to about 42° C, and preferably from about 35° C to about 37° C.

At a minimum, enhanced ribonucleic or proteolytic degradation of an RNA transcript or polypeptide, respectively, refers to a level of ribonucleic or proteolytic degradation that is at least about 5%, preferably at least about 10%, more preferably at least about 20%, even more preferably at least about 40%, even more preferably at least about 50%, even more preferably at least about 60%, even more preferably at least about 70%, even more preferably at least

- 28 -

about 80%, even more preferably at least about 90%, even more preferably at least about 100%, even more preferably at least about 150%, even more preferably at least about 200%, even more preferably at least about 400%, even more preferably at least about 600%, even more preferably at least about 1,000%, even more preferably at least about 2,000%, even more preferably at least about 4,000%, even more preferably at least about 6,000%, even more preferably at least about 8,000%, preferably at least about 10,000%, still even more preferably at least about 12,000%, greater than that of the RNA transcript or polypeptide in the absence of the destabilising element(s) or in the presence of a stabilising element(s). Assays for measuring RNA degradation are known to those of skill in the art. For example, RNA degradation can be measured using a range of assays disclosed for example by Ross, J (1995) or by Liu, J *et al.* (JBC 2000), which are based on the use of transcriptional inhibitors (Actinomycin D, DRB, cordycepin, alpha-amanitin), pulse labelling (radioactive nucleosides), cell-free decay methods (polysomes, cytosol or reticulocytes), or short-term promoter activation (fos promoter, see below). Assays for measuring degradation of proteins are also known to persons of skill in the art. For example, proteolytic degradation may be measured *in vitro* using a mammalian cell lysate assay including, but not restricted to, the reticulocyte lysate assay of Bachmair *et al* in U.S. Patent Serial No. 5,646,017. Alternatively, proteolytic degradation may be measured *in vivo* using cycloheximide or pulse-chase protocols as for example disclosed by Vazhappilly, R and Sucher, N (2002) or by Saito, T *et al.* (1998).

20

The RNA destabilising elements can be derived from any source and in particular the 3' UTR or 5' UTR regions of short-lived mRNAs often contain destabilising sequences. As used herein, the term "derived from" shall be taken to indicate that a particular integer or group of integers has originated from the species specified, but has not necessarily been obtained directly from the specified source.

25

The RNA destabilising sequences may be cloned from short-lived RNAs such as, for example; *c-fos*, *c-jun*, *c-myc*, *GM-CSF*, *IL-3*, *TNF-alpha*, *IL-2*, *IL-6*, *IL-8*, *IL-10*, *Urokinase*, *bcl-2*, *SGLT1* (*Na(+) coupled glucose transporter*), *Cox-2* (*cyclooxygenase 2*), *IL8*, *PAI-2* (plasminogen activator inhibitor type 2), *beta1-adrenergic receptor*, *GAP43* (5'UTR and 3'UTR).

- 29 -

AU-rich elements (AREs) and/or U-rich elements (UREs), including but not limited to single, tandem or multiple or overlapping copies of the nonamer UUAUUUA(U/A)(U/A) (where U/A is either an A or a U) (Lagnado *et al* 1994) and/or the pentamer AUUUA (Xu *et al* 1997) and/or the tetramer AUUU (Zubiaga *et al.* 1995).

5 RNA destabilising elements have also been described for example from phosphoenolpyruvate carboxy kinase mRNA (PEPCK), the Drosophila Bicoid gene, the human thioredoxin gene, heat stable antigen and soybean 10A5 gene.

10

Iron responsive elements and iron regulatory protein binding sites may also advantageously be incorporated into the instant vectors to modulate RNA stability and particularly, translational efficiency. Histone RNAs, particularly their 3'UTRs, are especially useful for modulating RNA stability in a cell-cycle dependent fashion.

15

Also contemplated are modifications to or permutations of the elements listed above. The term "tandem copies" allows for both duplication and/or non-duplication of one or more of the outer nucleotides. For example, tandem copies of the pentamer AUUUA, includes sequences such as AUUUAAUUUAUUUA as well as AUUUAAUUUAUUUA.

20

RNA destabilising elements may be identified and or modifications made thereto using a computational approach and database analysis (Dandekar T *et al*).

25

Accordingly, biologically active fragments as well as variants and derivatives of reference destabilising elements are encompassed by the present invention.

Eukaryotic expression vectors are contemplated.

30

In a related embodiment the present invention contemplates an expression vector comprising a transcribable polynucleotide which comprises a sequence of nucleotides encoding an RNA element which modulates the stability of a transcript corresponding to said transcribable

- 30 -

polynucleotide; wherein said RNA element is a stabilising element which increases the stability of said transcript.

In another related embodiment the present invention contemplates an expression vector

5 comprising a transcribable polynucleotide which comprises a sequence of nucleotides encoding an RNA element which modulates the stability of a transcript corresponding to said transcribable polynucleotide; wherein said RNA element is a stabilising element which increases the stability of said transcript, wherein said stabilising element is, or is derived from, a gene selected from *alpha2 globin*, *alpha1 globin*, *beta globin*, or *growth hormone*, which are

10 examples of long-lived mRNAs. As used herein, underscoring or italicising the name of a gene shall indicate the gene, in contrast to its protein product, which is indicated by the name of the gene in the absence of any underscoring or italicising. For example, “*alpha2 globin*” shall mean the *alpha2 globin* gene, whereas “*alpha2 globin*” shall indicate the protein product of the “*alpha2 globin*” gene.

15

The ability to destabilise a transcript and reduce the amount of protein produced by a cell will clearly be useful for a wide range of applications.

Another aspect of the present invention contemplates an expression vector comprising a

20 transcribable polynucleotide which comprises a sequence of nucleotides encoding an RNA element which modulates the stability of a transcript corresponding to said transcribable polynucleotide; wherein said RNA element is a destabilising element which reduces the stability of said transcript.

25 In another aspect, the present invention contemplates an expression vector comprising a transcribable polynucleotide which comprises a sequence of nucleotides encoding an RNA element which modulates the stability of a transcript corresponding to said transcribable polynucleotide; wherein said RNA element is a destabilising element which reduces the stability of said transcript, wherein the sequence of nucleotides encoding said destabilising

30 element is, or is derived from, a gene selected from *c-fos*, *c-jun*, *c-myc*, *GM-CSF*, *IL-3*, *TNF-alpha*, *IL-2*, *IL-6*, *IL-8*, *IL-10*, *Urokinase*, *bcl-2*, *SGLT1 (Na(+)-coupled glucose transporter)*,

- 31 -

Cox-2 (cyclooxygenase 2), IL-8, PAI-2 (plasminogen activator inhibitor type 2), beta-adrenergic receptor or GAP43.

In one particular embodiment the polynucleotide sequences encoding the RNA destabilising elements are linked to sequences encoding a protein of interest, which in turn is linked to a promoter of interest that is preferably modulatable (i.e., inducible or repressible) such that expression is turned on and then off modulation. In this application, the RNA destabilising elements typically serve to shorten the period of expression of a functional mRNA or protein. This may be applied *in vitro* or *in vivo*. For example, a cell cycle-specific promoter could be combined with the RNA instability elements to express a protein of interest, exclusively in certain stages of the cell cycle. The protein of interest may be a functional protein or a reporter protein. In the latter example, reporter levels can be used as an indicator of cell-cycle stage or cell proliferation.

15 Yet another aspect of the present invention contemplates an expression vector comprising a transcribable polynucleotide which comprises a sequence of nucleotides encoding an RNA element which modulates the stability of a transcript corresponding to said transcribable polynucleotide; wherein said RNA element is a destabilising element which reduces the stability of said transcript, wherein the sequence of nucleotides encoding said destabilising element is selected from any one of SEQ ID NOS 1 to 23, or biologically active fragments thereof, or variants or derivatives of these.

20

Even another aspect of the present invention contemplates an expression vector comprising a transcribable polynucleotide which comprises a sequence of nucleotides encoding an RNA element which modulates the stability of a transcript corresponding to said transcribable polynucleotide; wherein said RNA element is a destabilising element which reduces the stability of said transcript, wherein the sequence of nucleotides encoding said destabilising element is set forth in SEQ ID NO: 1, 2 or 22 or biologically active fragments, variants or derivatives thereof.

30

Another aspect of the present invention contemplates an expression vector comprising a

transcribable polynucleotide which comprises a sequence of nucleotides encoding an RNA element wherein said RNA element is a destabilising element which reduces the stability of said transcript and wherein said transcribable polynucleotide comprises a polynucleotide of interest and encodes a polypeptide.

5

One particular application is in the area of determining gene expression. Specifically, by reducing the amount of transcript produced in a cell it is possible to more accurately determine promoter or enhancer activity. In this application a reporter gene is used to determine promoter activity either directly, or indirectly as a fusion protein with another polypeptide whose 10 expression has been modulated by regulatory elements within the vector.

In one embodiment the RNA destabilising sequences are incorporated into the region encoding the 3'-UTR of the reporter mRNA. Alternatively or in addition, destabilising elements are incorporated into the 5'-UTR and/or protein coding region, which is preferably not essential 15 to, or does not interfere with, the selected activity of the encoded protein.

In a related embodiment the RNA destabilising sequences are used to destabilise a gene of interest when for example there is a need to accurately monitor or reduce its expression. Typically for this application, RNA destabilising elements are used in conjunction with 20 reporter protein destabilising elements.

The subject expression vectors have applications in a variety of gene expression systems where it is preferable to have a brief period of mRNA or protein expression or where it is preferable to minimise the time lag between changes in promoter activity and the resultant changes in 25 mRNA/protein levels.

Accordingly, yet another aspect of the present invention contemplates an expression vector comprising a transcribable polynucleotide which comprises a sequence of nucleotides encoding an RNA element wherein said RNA element is a destabilising element which reduces the 30 stability of said transcript and wherein said transcribable polynucleotide comprises a polynucleotide of interest and encodes a reporter polypeptide.

Even yet another aspect of the present invention contemplates an expression vector comprising a transcribable polynucleotide which comprises a sequence of nucleotides encoding an RNA element wherein said RNA element is a destabilising element which reduces the stability of 5 said transcript and wherein said transcribable polynucleotide comprises a sequence of nucleotides encoding a reporter polypeptide.

The expression vectors are designed for use in eukaryotic cell systems. It should be noted however that the RNA destabilising elements may be used in a wide range of eukaryotic and/or 10 plants systems including cells, tissues or whole organisms defined as yeast, insect, nematode, fish, bird or mammal. For use in plants, different promoters and possibly different reporters and RNA destabilising elements (e.g., DST sequences) may be used.

It is contemplated that the expression vectors of the present invention will incorporate standard 15 protein reporter molecules or destabilised reporter protein molecules. Standard reporter molecules are well known in the art.

Another aspect of the present invention contemplates the combination of a protein destabilising element (e.g., a DNA/RNA sequence encoding an intracellular protein degradation signal or 20 degron which may be selected from a destabilising amino acid at the amino-terminus of a polypeptide of interest, a PEST region or a ubiquitin) and an mRNA destabilising element (e.g., multiple copies of the nonamer UUAUUUAUU), such that both mRNA and protein are destabilised. For example, one such embodiment incorporates into an expression vector, a PEST sequence immediately upstream of the translation stop codon and 4 nonamers located 25 downstream of the stop codon (preferably 20nt or more from stop codon).

In this way, reporter protein may be destabilised both at the protein level and the mRNA level.

The destabilised reporter protein may be any suitable protein. For example, destabilised GFP 30 proteins are suitable, such as for example d1EGFP, d1EYFP and d1ECFP comprising the d1

mutant of MODC. The destabilised luciferase protein has been described by Leclerc G. *et al.* The MODC PEST sequence was used. The MODC from d1EGFP is also contemplated.

Any method of destabilising a polypeptide of interest is contemplated by the present invention.

5 For example, a polypeptide of interest can be modified to include a destabilising amino acid at its amino-terminus so that the protein so modified is subject to the N-end rule pathway as disclosed, for example, by Bachmair *et al* in U.S. Patent Serial No. 5,093,242 and by Varshavsky *et al.* in U.S. Patent Serial No. 5,122,463. In a preferred embodiment of this type, the destabilising amino acid is selected from isoleucine and glutamic acid, more preferably 10 from histidine tyrosine and glutamine, and even more preferably from aspartic acid, asparagine, phenylalanine, leucine, tryptophan and lysine. In an especially preferred embodiment, the destabilising amino acid is arginine. In some proteins, the amino-terminal end is obscured as a result of the protein's conformation (i.e., its tertiary or quaternary structure). In these cases, more extensive alteration of the amino-terminus may be necessary to make the protein subject 15 to the N-end rule pathway. For example, where simple addition or replacement of the single amino-terminal residue is insufficient because of an inaccessible amino-terminus, several amino acids (including lysine, the site of ubiquitin joining to substrate proteins) may be added to the original amino-terminus to increase the accessibility and/or segmental mobility of the engineered amino terminus.

20 Modification or design of the amino-terminus of a protein can be accomplished at the genetic level. Conventional techniques of site-directed mutagenesis for addition or substitution of appropriate codons to the 5' end of an isolated or synthesised antigen-encoding polynucleotide can be employed to provide a desired amino-terminal structure for the encoded protein. For 25 example, so that the protein expressed has the desired amino acid at its amino-terminus the appropriate codon for a destabilising amino acid can be inserted or built into the amino-terminus of the protein-encoding sequence. Where necessary, a nucleic acid sequence encoding the amino-terminal region of a protein can be modified to introduce a lysine residue in an appropriate context. This can be achieved most conveniently by employing DNA constructs 30 encoding "universal destabilising segments". A universal destabilising segment comprises a nucleic acid construct which encodes a polypeptide structure, preferably segmentally mobile,

- 35 -

containing one or more lysine residues, the codons for lysine residues being positioned within the construct such that when the construct is inserted into the coding sequence of the antigen-encoding polynucleotide, the lysine residues are sufficiently spatially proximate to the amino-terminus of the encoded protein to serve as the second determinant of the complete amino-
5 terminal degradation signal. The insertion of such constructs into the 5' portion of a antigen-encoding polynucleotide would provide the encoded protein with a lysine residue (or residues) in an appropriate context for destabilisation.

In another embodiment, the polypeptide of interest is modified to contain a PEST region,
10 which is rich in an amino acid selected from proline, glutamic acid, serine and threonine, which region is optionally flanked by amino acids comprising electropositive side chains. In this regard, it is known that amino acid sequences of proteins with intracellular half-lives less than 2 hours contain one or more regions rich in proline (P), glutamic acid (E), serine (S), and threonine (T) as for example shown by Rogers *et al.* (1986, *Science* 234 (4774): 364-368).
15 In yet another embodiment, the polypeptide of interest is conjugated to a ubiquitin or a biologically active fragment thereof, to produce a modified polypeptide whose rate of intracellular proteolytic degradation is increased, enhanced or otherwise elevated relative to the unmodified polypeptide.
20 Still another aspect of the present invention contemplates an expression vector comprising a transcribable polynucleotide which comprises a sequence of nucleotides encoding an RNA element which modulates the stability of a transcript corresponding to said transcribable polynucleotide; wherein said RNA element is a destabilising element which reduces the stability of said transcript, wherein said reporter protein is selected from Luciferase, Green
25 Fluorescent Protein, Red Fluorescent Protein, SEAP, CAT, or biologically active fragments thereof, or variants or derivatives of these.

Such vectors can be used to screen for drugs or treatments that alter the activity of that promoter. Compared to existing reporter vectors, a near "real-time" measurement of drug
30 action can be obtained.

- 36 -

Still another aspect of the present invention is directed to an expression vector comprising a transcribable polynucleotide which comprises a sequence of nucleotides encoding an RNA element which modulates the stability of a transcript corresponding to said transcribable polynucleotide; wherein said RNA element is a destabilising element which reduces the 5 stability of said transcript and wherein said vector comprises one or more members in any order selected from the group consisting of:

10 (i) a multiple cloning site for introducing a sequence of nucleotides, which site is preferably cleavable enzymatically or otherwise biochemically to provide a linearised vector into which PCR amplification products are clonable directly (e.g., an Ec1HK1 site);

15 (ii) a reporter gene;

(iii) a promoter and/or enhancer for regulating expression of said transcribable polynucleotide;

20 (iv) a polyadenylation sequence;

(v) a selectable marker gene; and

(vi) an origin of replication.

Another aspect of the present invention contemplates vectors or sets of vectors, particularly but 25 not exclusively, plasmids, with applications in the study or measurement or monitoring of gene expression (e.g., promoter activity). Many other vectors could also be used such as for example viruses, artificial chromosomes and other non-plasmid vectors.

One embodiment involves pairs or sets of plasmids, each containing one or more of the mRNA 30 destabilising sequences described above incorporated into a construct encoding a destabilised reporter protein such as, for example, d1EGFP, d1EYFP, d1ECFP or d1DsRed. One plasmid

(the control) from each pair or set contains a promoter 5' of the reporter encoding region. The promoter is comprised of elements which is modulatable (i.e., inducible or repressible) by exogenous treatments (e.g., the TRE combined with a minimal promoter such as mCMV; see Fig. 2c). Alternatively, a constitutively active promoter such as TS, SV40, CMV, TK or RSV 5 is used (see Fig. 2b). In plant systems the Top-ten promoter could replace TRE, and the 35S promoter of cauliflower mosaic virus can replace SV40 etc. Agrobacterium tumefaciens can be used in plants to facilitate gene transfer. The other plasmid(s) in the pair or set are identical to the control plasmid, except that a cloning site (MCS) replaces the promoter, and the reporter encoding region encodes a reporter similar to but distinguishable from the control reporter (see 10 Fig. 2a). In a preferred embodiment, the control plasmid encodes a destabilised variant of EGFP (e.g., d1EGFP, d1EYFP or d1ECFP) and the other vectors (test vectors) each encode a different colour variant from the same list (same protein half-life).

15 In other embodiments, a control and one of the test reporters are incorporated into a single vector, such as for example a bi-directional plasmid (see Fig. 3).

20 In the above embodiments, both control and test plasmids encode a destabilised mRNA, which in turn encodes a destabilised protein. Thus the time lag between decreased promoter activity and decreased reporter protein levels, is significantly reduced compared to the time lag with existing constructs. Similarly, increased promoter activity is more readily and quickly detectable due to the reduced levels of pre-existing mRNA and protein. Other differences 25 between the control and test constructs, which can lead to errors, are minimised by using fluorescent proteins that differ from each other by only a few small mutations. Compared to luciferase or other enzyme based assays, the fluorescent reporters described here, offer several other advantages including:

- Several different reporters can be measured in the same cells/samples.
- Live cells can be measured, allowing multiple time points of the same samples or 30 further manipulation post-measurement e.g., measurement of the same cells before and after treatment with a drug.

- Successfully transfected cells can be visualised by fluorescent microscopy. Therefore poor transfections can be identified simply by looking at the cells under a microscope, without further investment of resources.

5

- No substrates are required, therefore the method is less technically demanding, faster, less expensive and more accurate.

10

- Both control and test reporter expression can be measured simultaneously by flow cytometry (see advantages of flow cytometry below).

15

- Embodiments utilising TREs as the control promoter can only be used in Tet-On or Tet-Off cell lines, but as compared to other control promoters, exhibit less interference from or to the test promoter and are less affected by various stimuli used to examine inducibility of the test promoter. Thus, they provide a more accurate measurement of transfection efficiency and relative test promoter activity. Control reporter expression can be switched on or off as required and used to confirm the lack of promoter cross-talk or compensate for it if present.

20

- In another embodiment, the control and one of the test reporters described above are both incorporated into a single vector, preferably a bi-directional plasmid. Interference between the two promoters, which is a major drawback of previous dual promoter vectors, is minimised by using TREs in the control promoter. Such a single vector system prevents the inaccuracies of co-transfection studies.

25

The invention also provides vectors in which informative promoters or promoter fragments, are placed upstream of the reporter-encoding region. The present invention provides a simpler, quicker and more cost-effective reporter system for such assays when using utilising EGFP variants as opposed to luciferase or other enzymes as the reporter. Furthermore, the inclusion of mRNA instability elements allows a near real-time analysis.

30

- 39 -

Informative promoters include, but are not restricted to, cell cycle-dependent promoters (e.g., cyclin A, B, or D1, histone or topoisomerase I promoters), promoters activated by apoptotic (cell death) pathways and promoters/fragments linked to mitogenic signals (Table 1). Examples of informative enhancers that can be used include any of those used in Clontech's

5 Mercury Pathway Profiling Systems. Clontech's Mercury In Vivo Kinase Assay Kits represent another example of how the present invention can be used. In this example the promoter element is a TRE that is combined in cells with a chimeric TetR-transactivator protein that permits transcription from the TRE only when a specific kinase is active and can phosphorylate the transactivator domain of the fusion protein. Thus, the present invention can be used to

10 provide a more real-time measurement of specific kinase activity.

Even still another aspect of the present invention contemplates a cell transfected or transduced with a vector according to the present invention comprising a transcribable polynucleotide which comprises a sequence of nucleotides encoding an RNA element which modulates the

15 stability of a transcript corresponding to said transcribable polynucleotide.

In some applications the expression vectors or cells expressing the reporter constructs are inserted into an organism to allow measurement of reporter activity *in vivo*. In some of these applications, destabilised luciferase rather than destabilised EGFP variants may be the

20 preferred reporter. For example, transgenic mice expressing destabilised luciferase under the control of an informative promoter, can be used to measure the activity of that promoter in the tissues of a live mouse, using a photon camera (photon camera analysis is described by Contag, *et al*, 1997). The mRNA destabilising sequences serve to improve the temporal correlation between promoter activity and reporter levels, thus providing a significant improvement to

25 applications such as drug screening, which benefit from a near real-time measurement of promoter activity.

In some applications it is desirable to express, either *in vitro* in cell-based systems or *in vivo* in mammalian systems, both a reporter molecule and a functional gene product. This may

30 involve two separate mRNAs, each containing an mRNA destabilising element. Alternatively, an mRNA destabilising elements may be incorporated into a single destabilised transcript that gives rise to two separate proteins (e.g., using an internal ribosome entry site; IRES) or a fusion

- 40 -

protein comprised of the reporter and the functional gene product.

The invention also provides cell lines stably expressing these vectors (with or without a control). Such cells have applications in areas such as drug screening. For example, cells
5 containing a MAPK-dependent reporter vector provide a rapid and inexpensive method for testing the efficacy of drugs designed to inhibit MAPK or any pathway upstream of MAPK-dependent transcription in those cells. In SKBR3 human breast cancer cells, for example, MAPK activity is dependent on signalling from the overexpressed ErbB2 protein. Therefore, drugs that inhibit ErbB2, would cause a decrease in the fluorescence of SKBR3 cells containing
10 such a construct but not in cells lacking ErbB2. Alternatively, cells could be tested \pm drug and \pm a specific ligand or treatment that leads to MAPK activation via a different pathway, in order to monitor inhibition of that pathway. Cell lines (or organisms) stably expressing a vector linked to a cell-cycle-regulated promoter can be used as very fast, simple and inexpensive means for measuring cell-cycle progression or cell proliferation. Such cell lines have obvious
15 utility in drug screening and are contemplated in the present invention. Examples of cell-cycle regulated promoters are readily available, for example, (Lee, H *et al.* 1995), (Stein, J *et al.* 1996) and (Huet, X *et al.* 1996).

Another embodiment of the present invention includes vectors, for the study of post-
20 transcriptional regulation, particularly mRNA stability. The reporter is, for example, a destabilised variant of EGFP (e.g., d1EGFP, d1EYFP, d1ECFP), with a different color variant in each separate vector. The TRE (linked to a minimal promoter such as mCMV) is 5' of the reporter encoding region and drives transcription in a tetracycline (or doxycycline) dependent fashion. Other inducible promoter systems can also be used.

25 In one embodiment, the mRNA instability elements described above are not included and in their place, MCSs are located, primarily in the 3'-UTR (see Fig. 4a) but also in the 5'-UTR and/or coding region in some specific embodiments. Sequences thought to affect mRNA stability can be tested by cloning them into the appropriate cloning site of a vector containing
30 one color variant and measuring the rate of decrease in reporter levels after blocking transcription with tetracycline or doxycycline (see Fig. 7). If desired, the rate of decay can be

- 41 -

compared between the "test vector" and the "control vector," (which encodes a different colour EGFP variant and does not contain the sequence being tested) in the same cells.

The MCS may usefully comprise or work in conjunction with restriction endonuclease sites
5 which allow direct cloning of PCR products having overhangs (see below).

In another related embodiment of the invention, one or more mRNA instability element(s) are included to assist scientists specifically searching for mRNA stabilising elements. Similarly, other embodiments include mRNA stabilising element(s) to assist scientists specifically
10 searching for mRNA destabilising elements.

In other embodiments, the control and one of the test reporters are both incorporated into a single vector, preferably a bi-directional plasmid (see Fig. 4b).

15 Stabilising elements are useful for increasing levels of expressed protein for example during protein purification where high levels of protein are required or when a promoter is weak.

Interference between the two promoters and moreover, transcription effects of the element or various stimuli tested, is circumvented by using a TRE or similar element to drive both
20 reporters and by measuring reporter levels after addition of doxycycline (or tetracycline), which shuts off transcription from the vector.

Still another aspect of the present invention contemplates a cell transfected or transduced with a vector according to the present comprising a transcribable polynucleotide which comprises
25 a sequence of nucleotides encoding an RNA element which modulates the stability of a transcript corresponding to said transcribable polynucleotide; wherein said RNA element is a destabilising element which reduces the stability of said transcript.

A related aspect of the instant invention considers a genetically modified non-human organism
30 comprising a transcribable polynucleotide which comprises a sequence of nucleotides encoding an RNA element which modulates the stability of a transcript corresponding to said

- 42 -

transcribable polynucleotide; wherein said RNA element is a destabilising element which reduces the stability of said transcript.

Yet a further embodiment of the present invention contemplates a method for determining 5 expression of a polynucleotide of interest, said method comprising expressing said polynucleotide of interest from a reporter expression vector for a time and under conditions sufficient for RNA and protein synthesis to occur, said vector comprising a transcribable polynucleotide which comprises a sequence of nucleotides encoding a transcribed element and said polynucleotide of interest wherein said transcribed element modulates the stability of a 10 transcript corresponding to said transcribable polynucleotide; and wherein said expression vector comprises one or more members in any order selected from the group consisting of:

- (i) a multiple cloning site for introducing said polynucleotide of interest;
- 15 (ii) a reporter gene;
- (iii) a promoter for regulating expression of said polynucleotide of interest and/or a reporter gene, which promoter is preferably modulatable (e.g., using a tetracycline responsive element (TRE));
- 20 (iv) a polyadenylation sequence;
- (v) a selectable marker gene; and
- 25 (vi) an origin of replication;

and measuring the level or activity of the reporter over time compared to a control wherein said destabilising element enhances the temporal correlation between promoter or enhancer activity and reporter level or activity.

- 43 -

A combination of different RNA destabilising elements acting in combination is contemplated herein.

The present invention is further described by the further non-limiting Examples.

5

EXAMPLE 1
Cloning DNA Elements into Vectors

Cloning is carried out according to existing methods, using restriction enzyme sites in the MCS
10 or direct ligation of PCR products in the case of vectors with a "T overhang" in the MCS. With respect to post-transcriptional reporter vectors, however, the inclusion of a MCS in the 3'-UTR or other regions is a significant improvement over current vectors, which were designed for transcriptional or other studies and do not contain convenient cloning sites in these locations.

15

EXAMPLE 2
Transfection

Co-transfection of control and test vectors is performed as per existing methods (e.g., Fugene
[Boehringer Mannheim, Mannheim, Germany] or electroporation), except in the case of the
20 single (e.g., bi-directional) vector systems described above, which require only one vector and thus eliminate inaccuracies associated with co-transfection.

25

EXAMPLE 3
Measurement of Reporter Expression

An immediate advantage of the vGFP system is that reporter expression can be visualized directly in living cells, simply by viewing the tissue culture plate or flask under a fluorescent
30 microscope. Therefore, poor transfections can be identified and discarded before any additional time is wasted. Quantitative measurement can be performed using a fluorometer (e.g., 96 well

plate format) and since live cells can be measured, the same samples can be measured repeatedly e.g., in a time course.

A further advantage compared to luciferase and other enzyme based assays is that flow

5 cytometry can also be used to measure reporter levels.

EXAMPLE 4

Advantages of Using Flow Cytometry to Measure Reporter Levels

10 i. Two or more reporters (control and test) as well as additional parameters, can be measured individually in every cell at a rate of >2,000 cells per second. Therefore, in this application, the method yields thousands to hundreds of thousands of data points per sample versus one datum point for existing luciferase assays.

15 ii. Accurate measurement of transfection efficiency: This is useful for optimising transfection protocols. In addition to allowing comparison of different methods, it is also possible to measure both expression per cell and the proportion of cells expressing. This helps the investigator to determine the cause of any problems.

20 iii. Identification of co-transfection errors: Co-transfection studies are based on the premise that cells will take up and express an amount of control reporters, which is proportional to the amount of test plasmid taken up by the same cells. This is not always the case. By using the flow cytometry method described here, it is possible to correlate test versus control expression levels in different cells of the same sample. 25 Invalid samples can be identified by the lack of a good linear relationship between test and control reporter levels. Such errors go unnoticed in current methods.

30 iv. Simultaneous measurement of additional parameters: Fluorescent labelled antibodies can be used to quantify specific proteins on a cell by cell basis and this can be correlated with reporter levels to determine whether that protein affects gene expression via the element cloned into the reporter construct. Alternatively, the protein of interest can be expressed as a vGFP-fusion protein (the protein of interest fused to a GFP

- 45 -

variant) via transfection of an appropriate expression vector (inducible or non-inducible). Levels of the specific protein can then be correlated with the expression of a different GFP variant linked to a regulatory element of interest (co-transfected or transfected at a different time). In a third application, the vGFP reporter is linked to regulatory elements (e.g., promoters) thought to be cell cycle specific. Transfected cells are stained with a fluorescent DNA dye such as propidium iodide to measure DNA content, which is then correlated with reporter expression. In principle, several of the DNA constructs described herein, each containing a different vGFP, could be co-expressed and independently measured. Furthermore, other fluorescent markers could be used in conjunction with these vectors (singly or in multiples).

5

v. Cell Sorting: Using a cell sorter, it is possible to isolate viable vGFP expressing cells from the non-expressors. This technique can be used to select stably expressing cells or to remove non-expressors prior to assay initiation. Similarly, it is possible to remove 10 cells expressing very low and/or very high levels of vGFP. This can be used to generate a more homogeneous population and/or to remove cells expressing levels so high that they may not be physiological relevant or may perturb normal cellular function and/or 15 may otherwise adversely affect the data obtained from the DNA vectors described herein.

20

It is important to note that transient and stable transfections of expression vectors result in a cell population with very heterogeneous levels of expression. In general a thousand fold difference between the highest and lowest expressor is not unusual. The present invention not only offers a method for selecting homogeneous populations when required (see v above), but 25 can also utilise heterogeneity to the benefit of the scientist. For example, identifying co-transfection errors. Another example of this relates to (iv) above. To determine whether protein X affects transcription from promoter Y, then cells are transfected with a reporter construct expressing d1EGFP under the control of promoter Y. If required, cell sorting can be used to isolate cells transiently or stably expressing appropriate levels of d1EGFP. These cells are in 30 turn transiently transfected with a vector expressing a protein X-EYFP fusion protein. During flow cytometry, EGFP is plotted on one axis and EYFP on the other. A positive correlation

- 46 -

would indicate that protein X increases transcription from promoter Y and a negative correlation would indicate that protein X inhibits transcription from promoter Y.

Currently, scientists attempting to establish such a correlation would select several different clones of high versus low expressors of protein X. Each clone would then be separately transfected with a promoter Y-luciferase construct and the luciferase activities measured. The use of cell clones requires months of preparation and introduces many variables including pre-existing heterogeneity amongst the host cells and variable sites of vector integration (vector DNA may interfere with a specific gene at the integration site and this site is different for every clone). Furthermore, such a method yields very few data points, with each datum point obtained from a different transfection of a different clone. Thus, the new system is not only more versatile but is quicker and more accurate than existing methods.

EXAMPLE 5

15 Laser scanning cytometry (LSC)

Unlike flow cytometry, LSC measures multi-colour fluorescence and light scatter of cells on slides, and records the position and time of measurement for each cell analysed. This technique provides data equivalent to flow cytometry but has the advantage of being microscope slide based (Darzynkiewicz *et al.*, 1999; Kamentsky *et al.*, 1997). Owing to the fluorescence of GFP and its variants, the techniques described for flow cytometry are also applicable to LSC.

EXAMPLE 6

Specific Methods for Post-Transcriptional Assays

25

These are best summarised by using the example of a study aimed at determining whether a specific 3'-UTR fragment affects mRNA stability. Although this example is one of transient expression, stable transfection could also be used

30 (i). The 3'-UTR fragment is ligated into the 3'-UTR cloning site of the test vector and co-transfected with the control vector into a Tet-Off cell line. In the case of the bi-directional vector, no control vector is required. Indeed, the typical application does not

- 47 -

require a control reporter or vector since rate of decay can be measured in samples from within the same transfection. 5'-UTR fragments can be tested by inserting them into vectors with a 5'-UTR cloning site.

5 (ii). The cells are grown in the absence of doxycycline (or tetracycline) for 6-48 h to allow expression of both vectors. Alternatively, cells are grown with low doses of doxycycline (or tetracycline), for 6-48 h to block transcription and then switched to medium without doxycycline (or tetracycline) for 2-12 h to provide a brief burst of transcription.

10

(iii). High doses of doxycycline (or tetracycline) are then applied to shut off transcription from both vectors.

15

(iv). The fluorescence of both reporters is measured (by flow cytometry, fluorometry or LSC) in a time course following addition of doxycycline (or tetracycline).

If the cloned element confers mRNA instability, a more rapid decrease in "test" fluorescence will be seen compared to "control" fluorescence of the same cells or sample. Similar studies can be used to test an mRNA element's response to certain stimuli or its effect in different cells 20 or cells expressing different amounts of a specific protein, such as an RNA-binding protein. Applying the stimulus after doxycycline will determine whether pre-existing transcripts are affected by the stimulus. Inserting the element in different locations (e.g., 5'-UTR, 3'-UTR) will determine whether its function is dependent on position. Inserting a protein/polypeptide coding sequence (in frame) within the reporter-coding region of the vector, can be used to 25 determine the effect of that sequence on mRNA and protein stability.

RNA can be extracted from transfected cells and used to measure reporter mRNA directly.

- 48 -

EXAMPLE 7
Transcription Reporter Vectors

The vectors are plasmids suitable for expansion in *E. coli* and expression of a fluorescent reporter in eukaryotic cells. The plasmids may be used in sets. Each set is comprised of one or more "control" vectors and one or more "test" vectors. Every vector within a set expresses a similarly destabilised mRNA and a similarly destabilised fluorescent reporter protein. In addition to the standard features of such plasmids (ampicillin resistance, origin of replication etc.), each plasmid contains the following construct (see also Figs 2 and 3):

10 5'---- MCS/promoter----transcription start site---5'UTR---ATG--vEGFP encoding region -- stop codon—3'UTR with mRNA destabilising element--polyadenylation signal

Where:

15 **MCS/promoter** denotes either a multiple cloning site (test vectors; see Fig. 2a) or a constitutively active promoter such as SV40 (control vectors; see Fig. 2b) or an inducible promoter such as TRE-mCMV (control vector; see Fig2c).

20 **ATG** denotes a translation start codon.

Stop codon denotes a translation stop codon.

5'UTR denotes a 5' untranslated region.

25 **3'UTR with mRNA destabilising element** denotes a 3' untranslated region containing one or more of the mRNA destabilising elements outlined.

30 **vEGFP** denotes a destabilised variant of EGFP. One set of plasmids is provided for each type of destabilising modification (e.g., 1 hr half-life, 2 hr half-life). Within each set of plasmids,

- 49 -

one vector is provided for each different colour variant. For example, one set contains vectors expressing d1EGFP, d1EYFP, d1ECFP whereas another set expresses the d2 variants.

In other examples, the control and one of the test reporters described above are both

5 incorporated into a single vector, preferably a bi-directional plasmid (see Fig. 3).

EXAMPLE 8
Post-transcription Reporter Vectors

10 Similar to the transcription reporter “control” vectors that contain a TRE-mCMV promoter, except that the mRNA destabilising element in the 3'-UTR is replaced with a MCS (see Fig. 4a). In some embodiments, MCS are also located in the 5' UTR and/or coding region.

Such a construct can be used as a “test” or a “control” vector for the post-transcriptional assays
15 outlined herein.

In other examples, the control and one of the test reporters described above are both incorporated into a single vector, preferably a bi-directional plasmid (see Fig. 4b).

20 **EXAMPLE 9**
Reporter Vectors for Assaying Specific Pathways

Vectors similar to those described herein, into which a regulatory element has been inserted into the MCS for the purpose of studying or measuring the function of said regulatory element.
25 For example, plasmids similar to the transcription reporter plasmids outlined herein, except that they contain within the MCS, a promoter or promoter element(s) or enhancer(s) that are responsive to pathways such as those referred to in Table 1 and/or contain any of the following cis-acting enhancer elements as described in Clontech's Mercury Pathway Profiling Systems: AP1, CRE, E2F, GRE, HSE, ISRE, Myc, NFAT, NFκB, p53, Rb, SRE. The reporter is
30 preferably a destabilised version of GFP, luciferase or SEAP.

- 50 -

Cell lines and Mice for Assaying Specific Pathways

Cell lines or genetically modified mice stably expressing one or more of the vectors described herein.

5

EXAMPLE 10

Method of Use

10 The vectors described in this invention are used for experimentation in essentially the same manner as the existing vectors that they replace, with the exception of the new methods described herein.

Method of Construction

15 The vectors and DNA constructs outlined here are assembled using standard cloning techniques. The SV40 and TRE-mCMV promoters described here as well as the more standard components of plasmid vectors (e.g., origin of replication, antibiotic resistance or another selection gene) are readily available in a variety of common vectors. DNA sequences encoding the destabilised variants of EGFP (e.g., d1EGFP, d1EYFP, d1ECFP and d2EGFP, d2EYFP, 20 d2ECFP) are available from Clontech (Clontech Laboratories Inc., Palo Alto, CA, USA). DNA sequences encoding destabilised DsRed variants are constructed by fusing to the 3' end of the DsRed encoding region, sequences encoding the degradation domains (or mutants thereof) from short-lived proteins. For example, amino acids 422-461 from mouse ornithine decarboxylase, which contains a PEST sequence. Such sequences could potentially be derived 25 from existing dEGFP variants.

- 51 -

EXAMPLE 11

Summary

In summary the present vectors and methods are now available:

5

• Expression vectors or parts thereof that incorporate one or more mRNA instability elements in order to provide a relatively short-lived mRNA. Compared to existing expression vectors, the vectors claimed here provide kinetics of protein expression that correlate more closely with promoter activity. For example, the time lag between decreased promoter activity and decreased mRNA and protein levels is substantially reduced.

10

• Expression vectors or parts thereof encoding a destabilised mRNA that in turn, encodes a destabilised protein. Compared to existing vectors, the vectors claimed here provide kinetics of protein expression that correlate more closely with promoter activity.

15

• Expression vectors or parts thereof in which the mRNA destabilising elements are comprised of sequences cloned from short-lived mRNAs such as *c-fos*, examples of short-lived mRNAs include; *c-fos*, *c-myc*, GM-CSF, IL-3, TNF-alpha, IL-2, IL-6, IL-8, Urokinase, *bcl-2*, SGLT1 (Na⁺-coupled glucose transporter), Cox-2 (cyclooxygenase 2), IL8, PAI-2 (plasminogen activator inhibitor type 2), beta1-adrenergic receptor, GAP43 (5'UTR and 3'UTR) AU-rich elements (AREs) and/or U-rich elements, including but not limited to single, tandem or multiple or overlapping copies of the nonamer UUAUUUA(U/A)(U/A) (where U/A is either an A or a U) (Lagnado *et al* 1994) and/or the pentamer AUUUA (Xu *et al* 1997) and/or the tetramer AUUU (Zubiaga *et al.* 1995). Also included are minor modifications to or permutations of the elements listed above. The term "tandem copies," allows for both duplication and/or non-duplication of one or more of the outer nucleotides. For example, tandem copies of the pentamer AUUUA, includes sequences such as AUUUUAUUUAUUUA as well as AUUUAUUUAUUUA. The 3' UTR or 5' UTR regions of short-lived mRNAs often contain destabilising sequences.

20

25

30

- 52 -

- Expression vectors or parts thereof in which the mRNA destabilising elements were identified or validated using the vectors described herein, which provide substantially improved methods for identifying such elements.

5

- Expression vectors or parts thereof, in which the destabilised mRNA encodes a short-lived reporter protein such as a destabilised variant of EGFP or luciferase. Compared to existing reporter vectors, the vectors claimed here provide kinetics of reporter expression that correlate more closely with promoter activity. For example, the time lag between decreased promoter activity and decreased mRNA and protein levels is substantially reduced.

10

- Sets of reporter vectors or parts thereof that encode similarly destabilised mRNAs (similar to other vectors in the same set), which in turn, encode similarly (similar to other vectors in the same set) destabilised variants of EGFP or DsRed or other fluorescent markers. One or more vectors (control vectors) within each set contain a constitutive promoter (e.g., SV40, CMV, RSV, TK, TS; see Fig. 2b) or an inducible promoter (e.g., TRE-mCMV; see Fig. 2c), whereas the other vectors (test vectors) within each set contain a cloning site (e.g., MCS) in place of the promoter (e.g., see Fig. 2a). Applications of these vectors include but are not limited to the study or measurement of promoter activity. For example, a promoter element of interest can be cloned into the MCS of a test vector encoding d1EGFP and reporter expression measured relative to that of a control vector expressing d1EYFP. Also claimed is each individual vector described well as bi-directional vectors or other single vector systems that incorporate one test and one control reporter construct within the same vector (e.g., Fig. 3a and Fig. 3b). Compared to existing sets of reporter vectors, the vector sets claimed here offer the following advantages:

15

- a). A measurement of promoter activity that is closer to real-time.

20

- 25

30

- 53 -

5 b). Decreased errors due to the closer similarity between control and test constructs.

10 c). Decreased errors resulting from cross talk between test promoters and the control promoters. By utilising inducible promoters in the control vectors, such cross talk is minimised and/or identified and corrected for via measurement with and without induction.

15 d). Can be used in conjunction with the flow cytometry/LSC methods described.

20 • Reporter vectors or sets of reporter vectors or parts thereof that utilise an inducible promoter, preferably but not exclusively the tetracycline responsive element (TRE), to drive expression of a destabilised fluorescent reporter protein (preferably but not exclusively destabilised EGFP variants). Such vectors contain cloning sites in the 3'-UTR (e.g., Fig. 4a) and/or 5'-UTR and/or reporter coding region, such that regulatory elements or putative regulatory elements can be cloned into a vector expressing one color fluorescent reporter and, if required, compared to a control vector which expresses a different color reporter and does not contain the element of interest. Such vectors have applications in the study or measurement of post-transcriptional regulation, since transcription can be shut off as desired via the inducible promoter. The advantages offered by these vectors include those listed in b-d, the ability to separate post-transcriptional effects from transcriptional effects and also:

25 a). incorporation of convenient cloning sites, not present in other vectors; and

b). the technique is more rapid than any existing method.

30 • Single vector systems that essentially link one test and one control construct and described (e.g., Fig. 4b). Both test and control reporters are driven by an inducible promoter and the cloning sites allow ligation of regulatory elements into the test construct only. In addition to the advantages of vectors outlined, the single vector

- 54 -

systems eliminate problems and inaccuracies associated with co-transfection of separate test and control vectors.

- The use of flow cytometry or LSC to measure the levels of 2 or more fluorescent reporters expressed via the vectors outlined. In this application, the method yields thousands to hundreds of thousands of data points per sample versus one datum point for existing enzyme-based assays. Two or more reporters (control and test) as well as additional parameters (e.g., DNA content, levels of other proteins) can be measured individually in every cell. Also encompassed is the use of flow cytometry to correlate the levels of 2 or more reporters in multiple cells within the same sample and the utilisation of such data to optimise transfection protocols and/or identify problems associated with co-transfection. For example, invalid samples can be identified by the lack of a good linear relationship between test and control reporter levels. Such errors go unnoticed in current methods.
- Methods for utilising the post-transcriptional reporter vectors claimed. These methods are best summarised by using the example of a study aimed at determining whether a specific 3'-UTR fragment affects mRNA stability. Although this example is one of transient expression, stable transfection could also be used.
 - (i). The 3'-UTR fragment is ligated into the 3'-UTR cloning site of the test vector and co-transfected with the control vector into a Tet-Off cell line. In the case of the single vector system, no control vector is required. 5'-UTR fragments can be tested by inserting them into vectors with a 5'-UTR cloning site.
 - (ii). The cells are grown in the absence of doxycycline (or tetracycline) for 6-48 h to allow expression of both vectors. Alternatively, cells are grown with low doses of doxycycline (or tetracycline), for 6-48 h to block transcription and then switched to medium without doxycycline (or tetracycline) for 2-12 h to provide a brief burst of transcription.

- 55 -

(iii). High doses of doxycycline (or tetracycline) are then applied to shut off transcription from both vectors.

5 (iv). The fluorescence of both reporters is measured (by flow cytometry, fluorometry or LSC) in a time course following addition of doxycycline (or tetracycline).

If the cloned element confers mRNA instability, a more rapid decrease in "test" fluorescence will be seen compared to "control" fluorescence of the same cells or sample. Similar studies can be used to test an mRNA element's response to certain 10 stimuli or its effect in different cells or cells expressing different amounts of a specific protein, such as an RNA-binding protein. Applying the stimulus after doxycycline will determine whether pre-existing transcripts are affected by the stimulus. Inserting the element in different locations (e.g., 5'-UTR, 3'-UTR) will determine whether its function is dependent on position. Inserting a protein/polypeptide coding sequence (in 15 frame) within the reporter protein-coding region of the vector can be used to determine the effect of that sequence on mRNA and protein stability.

RNA can be extracted from transfected cells and used to measure reporter mRNA directly.

20 • Cell lines transiently or stably expressing one or more of the expression constructs or parts thereof claimed.

25 • Cell lines transiently or stably expressing one or more of the expression constructs or parts thereof claimed, wherein the expression construct contains a regulatory element that serves as a marker for the activation of signal transduction pathways associated with human disease and/or response to drug treatment. Such pathways include, but are not restricted to the list in Table 1 and those indicated elsewhere in this document (e.g., CRE, SRE, AP1, cyclin A, B and D1 promoters).

- 56 -

- Transgenic mice, knock-in mice or other genetically modified mice expressing one or more of the expression constructs or parts thereof claimed.

5 • Transgenic mice, knock-in mice or other genetically modified mice expressing one or more of the expression constructs or parts thereof claimed, wherein the expression construct contains a regulatory element that serves as a marker for the activation of signal transduction pathways associated with human disease and/or response to drug treatment. Such pathways include, but are not restricted to the list in Table 1.

10 • Destabilised variants of DsRed or the mutant DsRed1-E5. These can be constructed by fusing to the C-terminus of DsRed, degradation domains (or mutants thereof) from various unstable proteins. For example, amino acids 422-461 of mouse ornithine decarboxylase, which contains a PEST sequence (Li *et al.* 1998). Additional destabilising elements can also be added. Also contemplated are DNA constructs encoding destabilised variants of DsRed.

15 • Vectors encoding destabilised variants of DsRed outlined, including such vectors also containing the mRNA instability elements outlined.

20 • The following method for creating Tet-Off or Tet-On cell lines:
The tTA or rtTA expression vector, preferably a retrovirus, adenovirus or plasmid, is stably expressed in the cell line of interest using standard techniques and expressing cells are isolated via a drug resistance marker. These cells are then transiently transfected with a TRE-vGFP construct and subjected to several rounds of cell sorting by flow cytometry. For example, good Tet-Off cells would show no fluorescence in the presence of doxycycline and are sorted as such. After a further 5-48 hr without doxycycline, green cells are sorted. Finally, the cells are grown for a week or more without doxycycline and sorted a final time to eliminate stably transfected (green) cells.

25

30

- 57 -

EXAMPLE 12

Vectors Incorporating mRNA and Protein Destabilising Elements

The coding region of interest (e.g., a reporter such as EGFP or luciferase) could include
 5 combined sequence of a protein destabilising element (e.g., d1 mutant of MODC; Clontech, but also including other PEST sequences or other protein destabilising elements such as ubiquitination sites) and an mRNA destabilising element (e.g., AU-rich element).

For example, the stop codon of luciferase and DsRed is replaced with a Hind3 site (AAGCTT)
 10 to allow the addition of the sequence:
 AAGCTTAGCCATGGCTTCCCGCCGGCGGTGGCGGCAGGATGATGGCACGCTGC
 CCATGTCTTGTGCCAGGAGAGCGGGATGGACCGTCACCTGAGCCTGTGCTTCT
 GCTAGGATCAATGTGTAG which is Clontech's d1 mutant of MODC that confers a 1 hr
 half life to EGFP. This is followed by a linker (which becomes part of the 3'UTR and then:
 15 UUAUUUAUU GGC GG UUAUUUAUU CGGCG UUAUUUAUU GCGCG
 UUAUUUAUU ACTAG which contains 4 nonamers and connects to the Xba1 site of the
 parent vector (pGL3; Promega) also in the 3'UTR but further downstream.

EXAMPLE 13

Direct Ligation of PCR Products

Inclusion into the MCS of a vector of two separate but nearby RE recognition sites, which, when cut with that/those RE(s), leave a 3' overhang of a single T nucleotide at both ends of the remaining vector. For example, the recognition sequence for EclHK1 is GACNNN,
 25 NNGTC (cuts between 3rd and 4th N from 5' leaving a 3' overhang of a single N at each end). Two of these sites are incorporating into the MCS, such that the short region between them is released by digestion with EclHK1, leaving a linearised vector with a 3' overhang of a single N at each end. In this example, the upstream recognition sequence should be 5'GACNNTNNGTC3' and the downstream sequence 5'GACNNANNNGTC3'. After cutting
 30 with EclHK1, the large vector fragment will contain a single 3' T overhang at both ends (similar to Promega's pGEM-T Easy vector). This facilitates the direct ligation of PCR

- 58 -

products that are produced with a polymerase such as Taq, that yields a 5' A overhang. This constitutes a significant improvement over standard MCSs, which do not support direct ligation of PCR products without inclusion of RE sites into PCR primers and subsequent digestion of PCR product. This is also a significant improvement over the pGEM-T Easy 5 vector, which cannot be amplified (supplied as linear) and is useful only for subcloning (i.e., PCR products are typically ligated into pGEM-T Easy, amplified and then removed by RE digestion and subsequently cloned into the expression vector of interest). Thus, the present MCS permits direct ligation of PCR products without the need for digesting them with a RE (which is often problematic) or subcloning them into an intermediate vector.

10

EXAMPLE 14

Destabilised Reporter Model Shows Improved Real-Time Analysis

Plasmid reporter vectors were assembled in a pGL3-Basic (Promega) backbone (ampicillin 15 resistance gene etc.) using standard cloning techniques. A tetracycline-responsive element (TRE), derived from Clontech's pTRE-d2EGFP vector was inserted into the MCS. In some constructs the luciferase-coding region was replaced with the d1EGFP- or d2EGFP- coding sequence (including Kozak sequence) as defined by Clontech. This was achieved by PCR using appropriate primers with convenient 5' flanking RE sites. In some constructs, specific 20 examples of mRNA destabilising elements were cloned into the 3'UTR-encoding region. Typically, these sequences were prepared by synthesising and then hybridising the sense and antisense sequences. Flanking sequences provided overhanging "sticky ends" that are compatible with those generated when the 3'UTR-encoding region is cut with specific restriction enzymes. Following digestion of the vector with these enzymes and subsequent 25 purification, the hybridised oligomers were ligated into the vector using standard techniques. PCR of genomic DNA or cDNA from an appropriate source was used as an alternative method for obtaining the larger destabilising elements such as c-myc-ARE. Very small elements (e.g., 1 or 2 nonamers) were incorporated into a reverse PCR primer that contained a 5' flanking RE site and a 3' flanking region complementary to the pre-existing 3'UTR in the vector template. 30 Following PCR with an appropriate forward primer (complementary to the protein-coding region and overlapping an endogenous RE site), the PCR product was digested with the

- 59 -

appropriate RE sites and ligated into the original vector.

Nomenclature;

5 B = Vector backbone derived from Promega's pGL3-Basic

T = Tetracycline-responsive element (TRE), derived from Clontech's pTRE-d2EGFP vector and used as a promoter to drive transcription of the reporter.

G1 = GFP with 1 hr half-life used as reporter i.e., d1EGFP protein encoding sequence as defined by Clontech.

10 G2 = GFP with 2 hr half-life used as reporter i.e., d2EGFP protein encoding sequence as defined by Clontech.

L = Luciferase used as reporter i.e., The Firefly luciferase encoding sequence from pGL3-Basic (Promega).

R = DsRed2 used as the reporter

15 R1 = DsRed fused at the carboxy-end to the same MODC mutant as present in d1EGFP

N6 = 6 copies of the nonamer TTATTTATT (SEQ ID NO: 1) inserted into the 3'UTR-encoding region.

N4 = 4 copies of the nonamer TTATTTATT inserted into the 3'UTR-encoding region.

N2 = 2 copies of the nonamer TTATTTATT inserted into the 3'UTR-encoding region.

20 N1 = 1 copy of the nonamer TTATTTATT inserted into the 3'UTR-encoding region.

fos = The c-fos ARE as defined by Shyu et al (1989) inserted into the 3'UTR-encoding region i.e.,

S'AAAACGTTTATTGTGTTTAATTATTAAAGATGGATTCTCAGATATTAT
ATTTTATTATTATTTTT3'. (SEQ ID NO: 2).

25 myc = the myc ARE defined as follows

5'ATGCATGATCAAATGCAACCTCACAAACCTGGCTGAGTCTGAGACTGAAAGAT
TTAGCCATAATGTAAACTGCCTCAAATTGGACTTGGGCATAAAAGAACCTT
TTTATGCTTACCATCTTTTTCTTAACAGATTGTATTAAGAATTGTTT
TTAAAAAAATTAAAGATTACACAATGTTCTGTAAATATTGCCATTAAAT

30 GTAAATAACTT3' (SEQ ID NO:21)

Method:

Five micrograms of maxiprep quality DNA was transfected into ~50% confluent 10cm flasks of HeLa Tet-Off cells (Clontech) using Fugene reagent (Roche). ~Ten hours later, the flasks of cells were each split into ~12 small (6cm) dishes and then incubated overnight (~12-14 hrs).

5 At this time point (typically designated time zero or T_0), doxycycline was added to the culture media of most plates at a final concentration of 1 microgram per ml. Cells were trypsinised and collected at this and subsequent time points. For constructs expressing GFP, these samples were analysed by flow cytometry using standard FITC filters. Total GFP fluorescence was measured by gating out non-transfected cells (background fluorescence only) and then 10 multiplying the mean fluorescence per cell (with background fluorescence subtracted) by the number of positive cells. RFP fluorescence (DsRed) was measured similarly using appropriate filters. Cells transfected with luciferase-encoding vectors were lysed and measured in a luminometer using Promega's Dual Luciferase Assay methods and reagents.

15 Data are typically expressed as the percentage of reporter (fluorescence or luminescence) remaining, relative to time zero.

Since the doxycycline added at time zero causes a block in transcription of the reporter, the rate of decrease in reporter levels indicates the time lag between altered transcription and altered 20 reporter/protein levels. A prime purpose of the invention is to reduce this time lag and Figs 7, 8, 9 and 11-14 demonstrate that this is achieved.

As an example of the utility of this invention, a pharmaceutical company may wish to screen for drugs that reduce transcription of a gene involved in disease. The tetracycline/doxycycline-induced block in transcription from the TRE promoter is a model of such a system. Figs 7 and 25 8 show that with the standard luciferase reporter vectors, even a total block in transcription (with doxycycline) is not detectable as a decrease in luciferase activity within 10 hrs. The destabilised EGFP mutants represent an improvement in that the total block in transcription is detectable as a 50% decrease in EGFP fluorescence within 11 hrs (d2EGFP; BTG2) or 7 hrs 30 (d1EGFP; BTG1). However, when the latter reporter is combined with an mRNA destabilising element such as 4 copies of the nonamer UUAUUUAUU (BTG1N4), a 50% decrease in

- 61 -

reporter levels is detectable within 3 hrs. It follows that an increase in a transcription would also be detected sooner with constructs containing the destabilising elements (Roth, 1995).

Of course the action of doxycycline is not immediate so that part of the time lag is due to the
5 time required for this drug to induce a 100% transcriptional block. Therefore, the "Effective rate of decay" was measured by plotting data points subsequent to and relative to the time point at 4 hrs after addition of doxycycline (Fig. 9). The effective rate of decay therefore excludes the delay in drug action and is a combined effect of protein and mRNA half-lives. Fig. 9 shows the effective rate of decay with constructs containing 1, 2 or 4 nonamers. These data show that
10 4 nonamers are more efficient than 2, which is more efficient than 1. Furthermore, these data show that by combining a 1 hr half-life protein (d1EGFP) with 4 nonamers, an effective rate of decay of approximately 1 hr 20 mins can be achieved. This is very close to the 1 hr half-life of the protein and demonstrates an extremely short mRNA half-life. Further reduction could be achieved by combining 2 or more different mRNA instability elements (Fig. 13). However,
15 this is unlikely to be required for most applications. Applications that require a more moderate destabilising effect could utilise 1 or 2 nonamers, rather than 4.

With the standard luciferase reporter, luminescence actually increased after the addition of doxycycline. This is most apparent when the data is expressed on a linear scale (Fig. 8) and can
20 be explained, in part, by the delay in the action of doxycycline. However, even from 4 hrs onwards, no decay is evident, demonstrating the inadequacy of this reporter for measuring changes in transcription over time. A further problem of this vector is revealed in Fig. 10. These data relate to changes in reporter levels over time (24-34 hrs post transfection), in the absence of any treatment or drug. Reporter levels generally increase during the first 24 hrs post
25 transfection as the plasmids enter the cells and begin to be expressed. A decrease is generally seen from about 48 hrs as the plasmids are expelled from the cells. Therefore, measurements are typically taken between 24 and 48 hrs. In the absence of drugs or treatment, the new vector (BTG1N4), containing the instability elements, shows excellent stability of reporter levels. In contrast, the luciferase vector is clearly still ramping up expression levels. Constructs with
30 moderate stability (e.g., BTG1) showed intermediate results. Clearly reporters with longer mRNA and protein half-lives will undergo a more lengthy ramping up phase as indicated in

- 62 -

Fig. 10. The more stable expression levels seen with the new construct during the critical period of 24-34 hrs will facilitate accurate measurement and represent another advantage of the invention.

5 The rate of decrease in reporter levels can be compared between two or more constructs, which differ in their reporter mRNA sequence (e.g., in 3'UTR) but encode the same protein or different proteins with the same half-life (e.g., d2EGFP, d2EYFP). In this context, differences in the rate of decay indicate an effect of the altered mRNA sequence on mRNA stability. For example, the presence of 4 UUAUUUAUU nonamers as DNA TTATTTATT

10 (SEQ ID NO: 1) (Figs 7-9) or the c-fos ARE (Fig. 11) (SEQ ID NO: 2), within the 3'UTR significantly increased the rate of mRNA decay. In addition to demonstrating the effectiveness of these elements, the methods and vectors used also represent a substantially improved system for detecting other cis-acting mRNA stability/instability elements and this process is also encompassed herein.

15 As shown in Figures 12 to 14 mRNA destabilising elements work with Luciferase, GFP and DsRed notwithstanding the low level of homology between these reporters. DsRed has only 23% homology with EGFP. As shown in Figure 14 *myc* ARE (SEQ ID NO: 21) are effective and are also effective in combination with different destabilising elements.

20

EXAMPLE 15

mRNA Destabilising Elements

RNA destabilising elements in accordance with the present invention can be derived *inter alia* 25 from the 3'UTR of the following genes. In most cases, the full-length 3'UTR can be used. However, the U-rich and/or AU-rich elements can often be used alone.

30 a) Phosphoenolpyruvate carboxykinase (PEPCK) mRNA destabilising elements described by Laterza OF *et al.* Regions within 3' half of 3'UTR referred to as JW6 and JW7 i.e., GTATGTTAAATTATTTTATACACTGCC
CTTCTTACCTTCTTACATAATTGAAATAGGTATCCTGACCA (SEQ ID

NO: 4).

or the mutant thereof which does not contain a polyadenylation (AAUAAA) signal
i.e., 5'UUUCGUUAACUGUGUAUGUACAUUAUUAUUUUUUAAU
5
UGAUUAAAGCUGAUUACUGUGgAUccACAGCUUCAUGCCUUUGUAAGU
TTGATTAAAGCTGATTACTGTGgATccACAGCTTCATGCCTTGTAAAGTT
3' (SEQ ID NO: 8).

10 h) Sequences from the following genes, that include their respective ARE components
as described by Henics, T. *et al.*;

15 IFN- γ ARE
5'UCUAUUUAUUAUAAUAAAACAUUAUUUAUAUUAUGGG3' or as DNA
5'TCTATTATTAAATATTAAACATTATTATATATGGG3' (SEQ ID NO: 9).

20 i) IL-2 ARE
5'CUCUAUUUAUUAUAAAUAUAAAACUUUAUUUAUUUUGGAUGUAU
UGUUUACUAACUUUAGUGCUUCCACUUAAAACAUAUCAGGCUUCU
AUUUAUUUAAAUAUUAAAUAUUUAUUUAUUUAUU3' or as DNA
5'CTCTATT
ATTAAATATTAACTTAATTATTATTGGATGTATTGTTACTAATT
TAGTGCTTCCCACTAAAACATATCAGGCTCTATTATTAAATATT
AATTATTATATTATT3' (SEQ ID NO: 10).

25 j) c-myc ARE (see also SEQ ID NO:21)
5'AUAAAACCUAAUUUUUUUUAUUUAAGUACAUUUUGCUUUAAAGUU3'
or as DNA 5'ATAAACCCCTAATTTCATTAAAGTACATTGCTTTAAAG
TT3' (SEQ ID NO: 11).

30 k) IL-10
5'UAGAAUAUUUAUUACCUCUGAUACCUAACCCCCAUUUCUAUUUAU

- 65 -

UUACUGAGCUUCUCUGUGAACGAAUUAAGAAAGGCCAAUAAUAUA
AUUUUUUCAAUUUUAUUAUUUCA3' or as DNA 5'TAGAATATTTATT
ACCTCTGATAACCTCAACCCCCATTCTATTATTACTGAGCTCTGTG
AACGATTAGAAAGAACGCCAATTATAATTTTTCAATATTATTAT
TTTCA3' (SEQ ID NO: 12).

l) **bcl-2**
Sequences from the bcl-2 3'UTR that include all or part of the bcl-2 ARE as defined by Schiavone, N *et al.* 5'UCAGCUUUACUGCCAAAGGGAAUA
10 UCAUUUAUUUUUACAUUAUUAAGAAAAAGAUUUUUUUUAAGA
CAGUCCCAUAAAACUCCGUCUUUGGAAAUC3' (M13994 from nt 2371-
2475) or as DNA 5'TCAGCTATTACTGCCAAAGGGAAATATCATTATT
TTTACATTATTAAGAAAAAGATTATTATTAAGACAGTCCCACAAA
15 ACTCCGTCTTGGAAATC3' (SEQ ID NO: 13).

15 m) **TNF ARE** as described by Xu, N *et al.* 5'AUUAUUUAUUAUUUUAUUA
UUUAUUUAUUUA3' or as DNA 5'ATTATTATTATTATTATTATTATT
ATTAA3' (SEQ ID NO: 14).

20 n) **IL3 ARE** as described by Xu, N *et al.* 5'UAUUUUAUUCCAUUAAGGCUAUU
UAUUUAUGUAUUUAUGUAUUAUUUUUUU3' or as DNA 5'TATT
ATTCCATTAAGGCTATTATTATGTATTATGTATTATTTATT3'
25 (SEQ ID NO: 15).

o) The nonamer UUAUUUAUU as DNA TTATTATT (SEQ ID NO: 1)
As described by Zubiaga, A *et al.*

30 p) The nonamer UUAUUUA(U/A)(U/A) as DNA TTATTTA(T/A)(T/A) (SEQ ID
NO: 3) as described by Lagnado, C *et al.*

q) The pentamer AUUUA as described by Xu, N *et al.* or as DNA ATTTA (SEQ ID

- 66 -

NO: 16)

r) The tetramer AUUU or as DNA ATTT (SEQ ID NO: 17).

5 AU-rich elements (AREs) in general of both class I and class II as described by Chen, C and Shyu, A.

Plants have DST (downstream sequences) which act as destabilising elements. DST sequence are defined in: Newnan, T *et al.* A proposed consensus DST sequence is:

10 GGA_gN₂₋₉c**ATAGATT**aN₃₋₈(A/C)(T/A)(A/T)T**ttGT**A(T/C)

s) This is based on comparison of 9 different DST sequences.

Bold = conserved in 9/9 genes.

15 Capital = conserved in at least 7/9 genes

N2-9 = variable length region of 2-9 nucleotides; average = 5.

N3-8 = variable length region of 3-8 nucleotides; average = 6.

Distance from stop codon = 19-83 nt.

20 Further examples of DST sequences include the:

Soybean 10A5 gene:

5'GGAGN₅CATAGATTAN₈AAATTTGTAC3' (SEQ ID NO: 18).

25 Arabidopsis SAURAC1 gene:

5'GGAAN₉CATAGATCGN₈CAATGCGTAT3' (SEQ ID NO: 19).

DST sequences are an alternative to AU-rich elements for use in plants. Both AU-rich elements and DST sequences destabilise transcripts in plants.

30

t) Iron Responsive Element (IRE)

Thomson, A *et al.* 1999.

- 67 -

IREs contain consensus CAGUG in a hairpin-loop.

Examples:

Ferritin IRE:

5 GUUCUUGCUUCAACAGUGUUUGAACCGAAC or as DNA GTTCTTGCTTCA
ACAGTGTGTTGAACCGAAC (SEQ ID NO: 20).

Transferrin Receptor IRE:

GAUUAUCGGGAGCAGUGUCUUCAUAAUC or as DNA GATTATCGGGAG
CAGTGTCTTCCATAATC (SEQ ID NO: 21).

10

Iron Regulatory Proteins (IRPs; e.g., IRP1 and 2) bind IREs in an iron-dependent fashion. Binding is also modulated by various other stimuli and treatments (e.g., oxidative stress, nitric oxide, erythropoietin, thyroid hormone or phosphorylation by PKCs.

15

IREs can modulate both translational efficiency and mRNA stability. For example, the 5'UTR IRE in Ferritin mRNA blocks translation only when bound to an IRP. The IREs in the 3'UTR of Transferrin receptor mRNA inhibit mRNA decay when bound by an IRP. Therefore, IREs can be inserted into 5'UTR or 3'UTR of expression vectors to 20 provide expression that can be controlled by modulating iron levels or other stimuli.

Destabilising elements can be used with Clontech's Mercury Pathway Profiling vectors and *in vivo* kinase assay kits. Clontech produce 3 different protein destabilising elements, all containing a PEST sequence and all derived from the MODC gene. 25 Different mutant MODCs placed at the carboxy-end of EGFP provide protein half-lives of 1 hr, 2 hr and 4 hr. mRNA destabilising elements in accordance with the present invention can be used in conjunction with these and any other protein destabilising element (e.g., ubiquitination signals).

30 u) c-myc ARE may also be defined as: 5'ATGCATGATCAAATGCAACCTCAC
AACCTTGGCTGAGTCTGAGACTGAAAGATTAGCCATAATGTAAACTG

- 68 -

CCTCAAATTGGACTTGGCATAAAAGAACTTTTATGCTTACCATCTT
TTTTTTCTTAACAGATTGTATTAAGAATTGTTTAAAAAATTAA
AGATTTACACAATGTTCTGTAAATATTGCCATTAAATGTAAATAACT
TT3' (SEQ ID NO: 22).

5

Another useful mRNA element can be obtained from histone mRNA, Specifically, 3'UTR sequences including a consensus stem loop structure are described by Gallie, D et al:

10 TGA-N₂₀₋₄₀-CCAAAGGYYYUUYUNARRCCACCCA, where Y=pyrimidine, R=purine, N= any nucleotide or as DNA TGA-N₂₀₋₄₀-CCAAAGGYYYTTYTN
ARRRCCACCCA (SEQ ID NO: 23).

15 Such sequences can increase translational efficiency. Moreover, they are capable of directing mRNA decay specifically outside of S phase. Reporter constructs containing a cell-cycle-specific promoter, together with mRNA destabilising elements are contemplated in this invention as a tool for directing cell-cycle specific expression (e.g., of a reporter). The histone 3'UTR element offers an alternative for use with an S-phase or late G1 specific promoter, since it will direct increased mRNA decay in G2 relative to S-phase, thus further restricting protein expression to S phase.

20

Yet another use of 3'UTR elements in expression vectors is for the purpose of specifically localising the chimeric mRNA. For example, the utrophin 3'UTR is capable of directing reporter mRNA to the cytoskeletal-bound polysomes. mRNA stabilising elements are also contained in this 3'UTR (Gramolini, A, et al)

25

EXAMPLE 16

mRNA Stabilising Elements and Expression Vectors encoding a stabilised mRNA

30 Stabilising sequences may contain CT-rich elements and/or sequences derived from long-lived mRNAs (particularly 3'UTR regions)

- 69 -

CT-rich elements may contain (C/U)CCAN_xCCC(U/A)Py_xUC(C/U)CC as described by Holcik and Liebhaber, 1997.

CT-rich elements may contain the following element

5 CCTCCTGCCCGCTGGGCCTCCCAACGGGCCCTCCTCCCTCCTTGC or parts thereof, including CCTCC, CCTCCTGCC or CCCTCCTCCCTGG

A 14 nt pyrimidine-rich region from the 3'UTR of human beta-globin described by Yu and Russell is also contemplated for use as a stabilising element.

10

Examples of long-lived mRNAs from which stabilising elements may be derived include; Alpha2 globin, Alpha1 globin, beta globin. From human, mouse, rabbit or other species, bovine growth hormone 3'UTR.

15 The mRNA instability elements described herein generally act in a dominant-fashion to destabilise chimeric genes. It follows, therefore that mRNA stabilising elements are often recessive-acting. For example, insertion of a c-fos ARE into the rabbit beta-globin gene, results in a destabilised transcript despite the continued presence of mRNA stability elements (Shyu, A *et al.* 1989). Both alpha- and beta-globin mRNAs contain stability elements that have been mapped to their respective 3'UTRs, whereas zeta-globin mRNA lacks these elements and is less stable. Replacing the zeta-globin 3'UTR with that of alpha globin mRNA nearly doubles mRNA stability (Russell, J *et al.* 1998). However, such elements do not stabilise all transcripts. Therefore, the requirements for generating an expression vector that expresses a stable mRNA differ, dependent on the original mRNA that is to be stabilised. To create such a vector it is 20 generally preferable to include large segments from a stable gene such as alpha- or beta-globin. With these examples, such segments should preferably include the entire globin 3'UTR, replacing the endogenous 3'UTR. As exemplified with zeta-globin, this is sometimes sufficient. However, the further incorporation of protein-coding and/or 5'UTR sequences is often required. Generally, it is preferable to replace any endogenous AU- or U-rich regions, 25 which may act as dominant destabilising elements (these can be identified using the techniques described herein). Such regions in the 5'UTR or 3'UTR are simply replaced with alpha- or 30

- 70 -

beta-globin sequences from the same relative position. Instability elements from the coding region can be rendered non-functional by mutation to synonymous codons. The globin protein-coding region can be incorporated into the coding region of the gene of interest to create an N- or C-terminal fusion protein. However this is often not desirable and it is generally sufficient

5 to localise the globin protein-coding region (and 3'UTR) into the 3'UTR of the chimeric gene. This allows expression of the desired protein from a more stable transcript, thus markedly increasing levels of the protein. When the desired protein is a reporter or is fused to a reporter or can be easily distinguished from endogenous protein, the TRE vector system described herein (see Fig. 7) greatly facilitates the testing of chimeric constructs for mRNA stability.

10 Those skilled in the art will be aware that the invention described herein is subject to variations and modifications other than those specifically described. It is to be understood that the invention described herein includes all such variations and modifications. The invention also includes all such steps, features, compositions and compounds referred to or indicated in this

15 specification, individually or collectively, and any and all combinations of any two or more of said steps or features.

- 71 -

TABLE 1

Signal transducers that could be used in the present invention

Signal transducer
AKT (also called PKB)
Fas L / BID
JAK 7 Stat
MKK-47 / JNK
MTOR / p70 s6 kinase
NF κ B
p38
PKA / Rap1 B-raf
Ras / Raf
Wnt / GSK3
Erk 1&2

BIBLIOGRAPHY

Chen, C and Shyu, A. Trends Biochem. Sci. 1995: vol 20 465-470.
5

Chyi-Ying, A *et al.* MCB 1995: vol 15 (10) 5777-5788.

Contag, *et al.* Non-invasive localization of a light-emitting conjugate in a mammal United States Patent 5,650,135. July 22, 1997.
10

Cormack, *et al.* FACS-optimized mutants of the green fluorescent protein (GFP) United States Patent 5,804,387. September 8, 1998.

Dandekar T *et al* Bioinformation 1998: 14(3):271-278.
15

Darzynkiewicz. Laser-scanning cytometry: A new instrumentation with many applications. Exp Cell Res 1999;249:1-12.

Gallie, D *et al.* Nucleic Acids Res. 1996: vol24 (10); 1954-1962.
20

Gasdaska, JR *et al.* JBC 1999:vol 274 (36); 25379-25385.

Gossen, *et al.* Tight control of gene expression in eucaryotic cells by tetracycline-responsive promoters. United States Patent 5,464,758. November 7, 1995.
25

Gramolini, A, *et al.* JBC 2001: vol 154 (6) 1173-1183.

Henics, T. et al JBC 1999: vol 274 (24) 17318-17324.
30

Holcik and Liebhaber, 1997, PNAS vol 94 pp2410-2414.

- 73 -

Huet, X *et al.* Mol Cell Biol. 1996; vol 16 (7): 3789-3798.

Ibrahim, *et al.* Pitfall of an internal control plasmid: Response of *Renilla* luciferase (pRL-TK) plasmid to dihydrotestosterone and dexamethasone. Biotechniques 2000;29:682-684.

5

Kamentsky *et al.* Slide-based laser scanning cytometry. Acta Cytol 1997;41:123-43.

Li, *et al.* Generation of destabilised green fluorescent protein as a transcription reporter. J Biol Chem 1998;273:34970-34975.

10 Lagnado C *et al*, MCB, 14:7984-7995, 1994.

Laterza, OF *et al* Am J Physiol Renal Physiol. 2000: vol 279(5) F866-F873.

Leclerc G *et al*, Biotechniques 2000, 29(3) 590-595.

15

Lee, H *et al.* Gene Expr 1995; vol 4(3): 95-109.

Li, *et al.* Rapidly degrading GFP-fusion proteins. United States Patent 6,130,313 October 10, 2000.

20

Liu, J *et al.* JBC 2000; vol 275 (16): 11846-11851.

Newnan, T *et al.* The Plant Cell 1993: vol 5; 701-714.

25 Peng, S *et al.* MCB 1996: vol 6 (4) 1490-1499.

Ross, J. Microbiological Reviews. 1995: vol 59 (3):423-450.

Saito, T *et al.* Biochem Biophys Res Commun. 1998; vol 252 (3): 775-778.

30

- 74 -

Schiavone, N *et al.* FASEB J. 2000: vol 14 174-184.

Shyu *et al* 1989:Genes & Dev. Vol 3, pp60-72.

5 Stein, J *et al.* Int J Obes Relat Metab Disord. 1996 Mar;20 Suppl 3: S84-90.

Surdej, P and Jacobs-Lorena, M. MCB 1998 vol 18 (5) 2892-2900.

10 Thomson, A *et al.* Int. J Biochem Cell Biol. 1999: vol 31; 1139-1152.

Tsien, *et al.* Modified green fluorescent proteins. United States Patent 5,625,048. April 29, 1997.

15 Tsien, *et al.* Modified green fluorescent proteins United States Patent 5,777,079. July 7,

1998.

Vazhappilly, R and Sucher, N. Neurosci Lett. 2002; vol 318 (3): 153-157.

Xu W *et al*, MCB, 17(8):4611-4621, 1997.

20

Yu and Russell MCB Sept 2001 5879-88.

Zhou, Q *et al.* MCB 1998: vol 18 (2) 815-826.

25 Zubiaga *et al.* MCB 1995;15:2219-30.

- 75 -

CLAIMS

1. An expression vector comprising a transcribable polynucleotide which comprises a sequence of nucleotides encoding an RNA element which modulates the stability of a transcript corresponding to said transcribable polynucleotide.
2. An expression vector according to claim 1 wherein said RNA element is a destabilising element which reduces the stability of said transcript.
- 10 3. An expression vector according to claim 1 wherein said RNA element is a stabilising element which increases the stability of said transcript.
4. An expression vector according to claim 2 wherein said transcribable polynucleotide comprises a polynucleotide of interest and encodes a polypeptide.
- 15 5. An expression vector according to claim 4 wherein said polypeptide comprises a reporter protein.
6. An expression vector according to claim 2 wherein said transcribable polynucleotide comprises a sequence of nucleotides encoding a reporter protein.
- 20 7. A vector according to claim 1 or 2 comprising one or more members selected from the group consisting of:
 - 25 (i) a multiple cloning site for introducing a sequence of nucleotides;
 - (ii) a reporter gene;
 - (iii) a promoter and/or enhancer for regulating expression of said transcribable polynucleotide;
- 30

- 76 -

(iv) a polyadenylation sequence;

(v) a selectable marker gene; and

5

(vi) an origin of replication.

8. A vector according to claim 7 further comprising at least one site which is cleavable enzymatically or otherwise biochemically to provide a linearised vector into which PCR 10 amplification products are clonable directly.

9 A vector according to claim 2 wherein the sequence of nucleotides encoding said destabilising element is, or is derived from, a gene selected from *c-fos*, *c-jun*, *c-myc*, *GM-CSF*, *IL-3*, *TNF-alpha*, *IL-2*, *IL-6*, *IL-8*, *IL-10*, *Urokinase*, *bcl-2*, *SGLT1* (*Na⁺*-coupled glucose 15 transporter), *Cox-2* (cyclooxygenase 2), *IL-8*, *PAI-2* (plasminogen activator inhibitor type 2), *beta1-adrenergic receptor* or *GAP43*.

10. A vector according to claim 3 wherein the sequence of nucleotides encoding said stabilising element is, or is derived from, a gene selected from *alpha2 globin*, *alpha1 globin*, 20 *beta globin*, or *growth hormone*, *erythropoietin*, *ribonucleotide reductase R1* or *m1 muscarinic acetylcholine*.

11. A vector according to claim 5 wherein the sequence of nucleotides encoding said destabilising element is selected from any one of SEQ ID NOS 1 to 23, or biologically active 25 fragments thereof, or variants or derivatives of these.

12. A vector according to claim 11 wherein the sequence of nucleotides encoding said destabilising element is selected from SEQ ID NO: 1, 2 or 22, or biologically active fragments thereof, or variants or derivatives of these.

- 77 -

13. A vector according to claim 5 or 6 wherein said reporter protein is selected from Luciferase, Green Fluorescent Protein, Red Fluorescent Protein, SEAP, CAT, or biologically active fragments thereof, or variants or derivatives of these.
- 5 14. A vector according to claim 4 wherein said polypeptide comprises a protein destabilising element.
- 10 15. A vector according to claim 13 wherein said reporter protein comprises a protein destabilising element.
- 15 16. A vector according to claim 14 or 15 wherein said protein destabilising element is encoded by a sequence of nucleotides encoding a PEST sequence or a ubiquitin or a biologically active fragment thereof, or variant or derivative of these.
- 20 17. A cell comprising one or more vectors according any one of the preceding claims.
18. A cell according to claim 17 wherein said cell is a eukaryotic cell.
19. A cell according to claim 18 wherein said cell is a mammalian cell.
- 20 20. A cell according to claim 19 wherein said cell is a human cell.
- 25 21. A genetically modified non-human organism comprising one or more of the vectors according to any one of claims 1 to 16.
- 30 22. A method for determining expression of a polynucleotide of interest, said method comprising expressing said polynucleotide of interest from an expression vector for a time and under conditions sufficient for RNA and protein synthesis to occur, said vector comprising a transcribable polynucleotide which comprises said polynucleotide of interest and a sequence of nucleotides encoding an RNA element which modulates the stability of a transcript corresponding to said transcribable polynucleotide; and wherein said expression vector

comprises one or more members selected from the group consisting of:

- (i) a multiple cloning site for introducing a sequence of nucleotides;
- 5 (ii) a reporter gene;
- (iii) a promoter and/or enhancer for regulating expression of said transcribable polynucleotide ;
- 10 (iv) a polyadenylation sequence;
- (v) a selectable marker gene; and
- (vi) an origin of replication;

15 and measuring the level and/or functional activity of an expression product of the transcribable polynucleotide over time compared to a control wherein said element enhances the temporal correlation between the activity of the promoter and/or enhancer that is operably connected to said transcribable polynucleotide and the level and/or functional activity of said expression product.

23. A method according to claim 22 wherein the transcribable polynucleotide comprising a sequence of nucleotides encoding said RNA destabilising element is, or is derived from, a gene selected from *c-fos*, *c-jun*, *c-myc*, *GM-CSF*, *IL-3*, *TNF-alpha*, *IL-2*, *IL-6*, *IL-8*, *IL-10*, *Urokinase*, *bcl-2*, *SGLT1* (*Na(+) -coupled glucose transporter*), *Cox-2* (*cyclooxygenase 2*), *IL-8*, *PAI-2* (*plasminogen activator inhibitor type 2*), *beta1-adrenergic receptor* or *GAP43*.

24. A method according to claim 22 wherein the transcribable polynucleotide encoding said RNA destabilising element comprises a sequence of nucleotides as set forth in any one of SEQ ID NOS 1 to 23, or a biologically active fragment thereof, or variants or derivatives of these.

25. A method according to claim 22 wherein the transcribable polynucleotide encoding said RNA destabilising element comprises a sequence set forth in SEQ ID NO: 1, 2 or 22, or a biologically active fragment thereof, or variants or derivatives of these.

5

26. A method for identifying a nucleotide sequence encoding an RNA element which modulates the stability of an RNA transcript, said method comprising introducing a test nucleotide sequence into an expression vector whereby said nucleotide sequence is connected to a polynucleotide encoding a reporter protein to form a transcribable polynucleotide which 10 is operably connected to a promoter and/or enhancer; expressing said transcribable polynucleotide for a time and under conditions sufficient for RNA and protein synthesis to occur; and wherein said expression vector comprises one or more members selected from the group consisting of:

. 15 (i) a multiple cloning site for introducing said test nucleotide sequence;

 (ii) a polyadenylation sequence;

 (iii) a selectable marker gene; and

20

 (iv) an origin of replication;

and measuring the level and/or functional activity of an expression product of said transcribable polynucleotide over time compared to that of a control vector in the absence of 25 said nucleotide sequence, wherein a level and/or functional activity which is different to that of the control vector over that time is indicative of a nucleotide sequence that encodes said RNA element.

27. The method of claim 26, wherein the promoter is modulatable.

30

- 80 -

28. The method of claim 27, wherein the promoter is inducible.
29. The method of claim 27, wherein the promoter is repressible.
- 5 30. The method of claim 26, wherein the expression product whose level and or functional activity is measured is said reporter protein.
- 10 31. The method of claim 26, wherein said reporter protein is selected from Luciferase, Green Fluorescent Protein, Red Fluorescent Protein, SEAP, CAT, or biologically active fragments thereof, or variants or derivatives of these.
32. The method of claim 31, wherein said reporter protein comprises a protein destabilising element.
- 15 33. The method of claim 32, wherein said protein destabilising element is encoded by a sequence of nucleotides encoding a PEST sequence or a ubiquitin or a biologically active fragment thereof, or variant or derivative of these.

1/14

Figure 1.**Expression Vectors Encoding a Destabilised mRNA**

Any promoter or promoter element



Protein or polypeptide encoding region



mRNA destabilising element



Polyadenylation signal




5'-untranslated region (5'-UTR)





3'-untranslated region (3'-UTR)

2/14

Figure 2.**Transcription Reporter Vectors****Fig. 2a. Vector Series 2****Fig. 2b. Vector Series 3****Fig. 2c. Vector Series 4**

3/14

Figure 3.
Bi-directional Transcription Reporter Vectors

Fig. 3a. Vector Series 5**Fig. 3b. Vector Series 6**

- SV4** → SV40 or other constitutive
- TRE** → Tetracycline Responsive
- mCMV** → Minimal Cytomegalovirus (CMV)
- vEGFP** → Region encoding anyenhanced green fluorescent protein
Each vector in the series encodes a
- MCS** → Multiple Cloning Site (any site useful for inserting)
- pA** → Polyadenylation
- → 5'-untranslated region (5'-)
- → 3'-untranslated region (3'-)
- DE** → mRNA destabilising
- → Spacer region to separate promoters. Can contain additional polyadenylation signals.

4/14

Figure 4.**Reporter Vectors For Studying Post-transcriptional Regulation****Fig. 4a. Vector Series 7****Fig. 4b. Vector Series 8****TRE**

Tetracycline Responsive Element

mCMV

Minimal Cytomegalovirus (CMV) promoter

vEGFPRegion encoding any variant of enhanced green fluorescent protein (EGFP)
Each vector in the series encodes a different variant.**MCS**

Multiple Cloning Site (any site useful for inserting DNA fragments)


pA

Polyadenylation signal


5'-untranslated region (5'-UTR)

3'-untranslated region (3'-UTR)


5/14

Figure 5.**Evidence For Errors Associated with Co-transfection in Luciferase-based**


6/14

Figure 6.**Evidence For Errors Associated with Dual Luciferase Assay.**


7/14

Figure 7.


8/14

Figure 8.

9/14


Figure 9.

10/14

Figure 10


11/14

Figure 11




12/14

Figure 13




13/14

Figure 13



14/14

Figure 14

SEQUENCE LISTING

<110> Gene Stream Pty Ltd
<120> Novel Expression Vectors
<130> 2510548/VPA
<160> 23
<170> PatentIn version 3.0

<210> 1
<211> 9
<212> DNA
<213> firefly

<400> 1
ttatttattt 9

<210> 2
<211> 75
<212> DNA
<213> Mammalian

<400> 2
aaaacgtttt attgtgtttt taatttattt attaagatgg attctcagat atttatattt 60
ttattttattt tttttt 75

<210> 3
<211> 9
<212> DNA
<213> Mammalian

<400> 3
ttatttaww 9

<210> 4
<211> 73
<212> DNA
<213> Mammalian

<400> 4
gtatgtttaa attattttta tacactgccc tttcttacct ttctttacat aattgaaata 60
ggatatcctgaa cca 73

<210> 5
<211> 53
<212> DNA
<213> Mammalian

<400> 5
agtaatattt atatatttat atttttaaaa tatttattta ttatatttattt taa 53

<210> 6
<211> 70
<212> DNA
<213> Mammalian

<400> 6
ttttattgtg ttttaattt atttattaag atggattctc agatattttat atttttat 60
tattttttt 70

<210> 7
<211> 89
<212> DNA
<213> Mammalian

<400> 7
tttcgttaac tgtgtatgta catatatata tttttaatt tgattaaagc tgattactgt 60
gaataaacag cttcatgcct ttgtaagtt 89

<210> 8
<211> 89
<212> DNA
<213> Mammalian

<400> 8
tttcgttaac tgtgtatgta catatatata tttttaatt tgattaaagc tgattactgt 60
ggatccacag cttcatgcct ttgtaagtt 89

<210> 9
<211> 36
<212> DNA
<213> Mammalian

<400> 9
tctatttattt aatatttaac attatttata tatggg 36

<210> 10
<211> 124
<212> DNA
<213> Mammalian

<400> 10
ctctattttat ttaaatattt aacttaattt tattttgga tgtattgttt actaactttt 60
agtgcgtcccc actaaaaaca tatcaggctt ctatattttt aaatatttaa attttatattt 120
tattt 124

<210> 11
<211> 46
<212> DNA
<213> Mammalian

<400> 11

ataaaacccta atttttttta ttaagtaca ttttgctttt aaagtt	46
<210> 12	
<211> 119	
<212> DNA	
<213> Mammalian	
<400> 12	
tagaatattt attacctctg atacotcaac ccccatctt. atttattttac tgagcttctc	60
tgtgaacgat ttagaaagaa gcccaatatt ataattttt tcaatattta ttatttca	119
<210> 13	
<211> 105	
<212> DNA	
<213> Mammalian	
<400> 13	
tcagctattt actgccaaag gaaatatca ttatttttt acattattaa gaaaaaagat	60
ttatttatcc aagacagtcc catcaaaact ccgtctttgg aaatc	105
<210> 14	
<211> 34	
<212> DNA	
<213> Mammalian	
<400> 14	
attattttattt atttattttat tattttatcc ttta	34
<210> 15	
<211> 55	
<212> DNA	
<213> Mammalian	
<400> 15	
tattttatttcc cattaaggct atttattttat gtatttatgt atttattttat ttatt	55
<210> 16	
<211> 5	
<212> DNA	
<213> Mammalian	
<400> 16	
attta	5
<210> 17	
<211> 4	
<212> DNA	
<213> Mammalian	
<400> 17	
attt	4

<210> 18		
<211> 36		
<212> DNA		
<213> Plant		
<220>		
<221> misc_feature		
<223> n is any nucleotide		
<400> 18		
ggagnnnnnc atagattann nnnnnnaat ttgtac		36
<210> 19		
<211> 40		
<212> DNA		
<213> Plant		
<220>		
<221> misc_feature		
<223> n is any nucleotide		
<400> 19		
ggaannnnnn nnncatagat cgnnnnnnnn caatgcgtat		40
<210> 20		
<211> 30		
<212> DNA		
<213> Mammalian		
<400> 20		
gttcttgctt caacagtgtt tgaacggaac		30
<210> 21		
<211> 29		
<212> DNA		
<213> Mammalian		
<400> 21		
gattatcggg agcagtgtct tccataatc		29
<210> 22		
<211> 226		
<212> DNA		
<213> Mammalian		
<400> 22		
atgcatgatc aaatgcaacc tcacaacctt ggctgagtct tgagactgaa agattttagcc		60
ataatgtaaa ctgcctcaaa ttggactttg ggcataaaag aactttttta tgcttaccat		120
ctttttttt tctttaacag atttgtatTTT aagaattgtt tttaaaaaat tttaagatTTT		180
acacaatgtt tctctgtaaa tattgccatt aaatgtaaat aacttt		226

<210> 23
<211> 26
<212> DNA
<213> Mammalian

<220>
<221> misc_feature
<223> Y is pyrimidine
R is purine
N is any nucleotide

<400> 23
ccaaaggyyy ttytnarrrc caccca

26

INTERNATIONAL SEARCH REPORT

International application No.
PCT/AU02/00351

A. CLASSIFICATION OF SUBJECT MATTER												
Int. Cl. ⁷ : C12N 15/67												
According to International Patent Classification (IPC) or to both national classification and IPC												
B. FIELDS SEARCHED												
Minimum documentation searched (classification system followed by classification symbols) SEE BELOW												
Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched SEE BELOW												
Electronic data base consulted during the international search (name of data base and, where practicable, search terms used) STN (WPIDS): untranslated region and (destab? or stab?)												
C. DOCUMENTS CONSIDERED TO BE RELEVANT												
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.										
X,Y	WO 99/14346, A (Sequitur, Inc) 25.03.99; see pages 4 and 11-25.	1-10; 22 and 26										
X,Y	WO 95/29244, A (Wisconsin Alumni Research Foundation) 02.11.95; see page 5 and claims	1-10, 22 and 26										
X,Y	Oncogene 11, pp 2127-2134 (1995) Veyrune et al "c-fos mRNA instability determinants present within both the coding and the 3' non coding region link the degradation of this mRNA to its translation".	1-10, 22 and 26										
<input checked="" type="checkbox"/> Further documents are listed in the continuation of Box C		<input checked="" type="checkbox"/> See patent family annex										
<p>* Special categories of cited documents:</p> <table style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 20%; vertical-align: top;">"A" document defining the general state of the art which is not considered to be of particular relevance</td> <td style="width: 20%; vertical-align: top;">"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention</td> </tr> <tr> <td style="vertical-align: top;">"E" earlier application or patent but published on or after the international filing date</td> <td style="vertical-align: top;">"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone</td> </tr> <tr> <td style="vertical-align: top;">"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)</td> <td style="vertical-align: top;">"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art</td> </tr> <tr> <td style="vertical-align: top;">"O" document referring to an oral disclosure, use, exhibition or other means</td> <td style="vertical-align: top;">"&" document member of the same patent family</td> </tr> <tr> <td style="vertical-align: top;">"P" document published prior to the international filing date but later than the priority date claimed</td> <td></td> </tr> </table>			"A" document defining the general state of the art which is not considered to be of particular relevance	"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention	"E" earlier application or patent but published on or after the international filing date	"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone	"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art	"O" document referring to an oral disclosure, use, exhibition or other means	"&" document member of the same patent family	"P" document published prior to the international filing date but later than the priority date claimed	
"A" document defining the general state of the art which is not considered to be of particular relevance	"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention											
"E" earlier application or patent but published on or after the international filing date	"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone											
"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art											
"O" document referring to an oral disclosure, use, exhibition or other means	"&" document member of the same patent family											
"P" document published prior to the international filing date but later than the priority date claimed												
Date of the actual completion of the international search 10 May 2002	Date of mailing of the international search report 17 MAY 2002											
Name and mailing address of the ISA/AU AUSTRALIAN PATENT OFFICE PO BOX 200, WODEN ACT 2606, AUSTRALIA E-mail address: pct@ipaustralia.gov.au Facsimile No. (02) 6285 3929	Authorized officer  MADHU K. JOGIA Telephone No : (02) 6283 2512											

INTERNATIONAL SEARCH REPORT

International application No.
PCT/AU02/00351

C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT		
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X,Y	Nucleic Acids Research 27, pp 1164-1673 (1999) Maurer et al "An AU-rich sequence in the 3'-UTR of plasminogen activator inhibitor type 2 (PAI-2) mRNA promotes PAI-2 mRNA decay and provides a binding site for nuclear HuR"	1-10, 22 and 26
X,Y	Molecular and Cellular Biology 21, pp 721-730 (Feb 2001) Dean et al "The 3' Untranslated region of tumor necrosis factor alpha mRNA is a target of the mRNA-stabilizing factor HuR".	1-10, 22 and 26
X	J Biol Chem 275, pp 30248-30255 (2000) Provost et al "Length increase of the human α -globin 3'-untranslated region disrupts stability of the pre-mRNA but not that of the mature mRNA"	1-10, 22 and 26
X	J Biol Chem 275, pp 12963-12969 (2000) Short et al "Structural determinants for post-transcriptional stabilization of lactate dehydrogenase A mRNA by the protein kinase C signal pathway"	1-10, 22 and 26
X	J Biol Chem 273, pp 15749-15757 (1998) Yeilding et al "c-myc mRNA is down-regulated during myogenic differentiation by accelerated decay that depends on translation of regulatory coding elements".	1-10, 22 and 26
X	Molecular and Cellular Biology 17, pp 2698-2707 (1997) Yeilding et al "Coding elements in exons 2 and 3 target c-myc mRNA downregulation during myogenic differentiation".	1-10, 22 and 26

INTERNATIONAL SEARCH REPORT

Information on patent family members

International application No.

PCT/AU02/00351

This Annex lists the known "A" publication level patent family members relating to the patent documents cited in the above-mentioned international search report. The Australian Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

Patent Document Cited in Search Report		Patent Family Member			
WO	9914346	AU	93193/98	CA	2304982
WO	9529244	AU	22959/95	US	5587300

END OF ANNEX